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COMPOUNDS AFFECTING CHOLESTEROL 
ABSORPTION 
STATEMENT AS TO FEDERALLY SPONSORED 
RESEARCH 
Funding for the work described above herein was pro- 
vided in part by the federal government, which may have 
certain rights in the invention. This application was sup- 
ported by government funding from the following agencies: 
NASAunder grant number NCC8-131, National Institute of 
Health under grant number CA86842, and National Science 
Foundation under grant number 0078921. 
TECHNICAL FIELD 
This invention relates to novel organic compound and 
methods for their synthesis. More particularly, the invention 
relates to novel compounds affecting lymphatic absorption 
of cholesterol. 
BACKGROUND 
Atherosclerosis is a major cause of heart attack, stroke, 
and gangrene of the extremities and can be attributed 
directly to having high levels of cholesterol in the body. 
Cholesterol can enter the body by absorption from foods by 
the intestinal mucosal cells and the lymphatic system (i.e., 
exogenous sources). Cholesterol also is produced in the liver 
by a sequence of enzymatic reactions (i.e., endogenous 
biosynthesis). Endogenous biosynthesis of cholesterol 
involves a key enzyme, HMG-CoA (3-hydroxy-3- 
methylglutaryl coenzyme A) reductase. HMG-CoA reduc- 
tase inhibitors can be used to lower total plasma cholesterol 
in patients with primary hypercholesterolemia. Effective 
inhibition of HMG-CoA reductase is realized by drugs such 
as Lovastatin (sold as Mevacor from Merck Co.), Mevalotin 
(from Sankyo Co., Japan), and analogs thereof (e.g., com- 
pounds sold under the trade names Sivastatin, Mevastatin, 
and Pravastatin). Exogenous sources of cholesterol, 
however, are not affected by these drugs. Various com- 
pounds have been reported to be useful for lowering cho- 
lesterol absorption. See, e.g., U.S. Pat. Nos. 5,246,960, 
5,175,186,5,215,972,5,495,048,5,856,503, and 5,637,771. 
Currently, a lipase inhibitor termed XenicalB has been 
offered for obesity management. XenicalB has been 
reported to achieve a slight reduction in cholesterol. 
SUMMARY 
The invention features a compound of Formula I: 
R, can be independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
2 
alkoxyalkyl ,  haloalkoxy,  haloalkoxyalkyl ,  aryl ,  
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, 
N-alkyl-N-arylsulfamyl ,  carboxy,  carboxyalkyl ,  
alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, 
alkoxycarbonylalkyl,  amido, N-alkylamido, N-N- 
dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, 
N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
10 amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, 
cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy. 
R, can be independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
20 a1 ko  x y alk y 1, halo a1 ko  x y, halo a1 ko  x y a1 k y 1, ar y 1, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, 
N-alkyl-N-arylsulfamyl ,  carboxy,  carboxyalkyl ,  
alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, 
alkoxycarbonylalkyl,  amido, N-alkylamido, N-N- 
dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, 
N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
30 cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, 
cyano, nitro, sulfonate, alkylsilyl, or phenylselenyl, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy; 
2s 
3s 
R, can be independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
a lkoxyalkyl ,  haloalkoxy,  haloalkoxyalkyl ,  aryl ,  
40 heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, 
N-alkyl-N-arylsulfamyl ,  carboxy,  carboxyalkyl ,  
alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, 
alkoxycarbonylalkyl,  amido, N-alkylamido, N-N- 
dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, 
N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
SO cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, 
cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy. 
4s 
5s 
R, can be independently hydrido, alkyl, or hydroxyalkyl. 
R, can be independently hydrido, alkyl, or hydroxyalkyl. 
In some embodiments, R, is halo, R, and R, are hydroxy, 
and R, and R, are alkyl in the compound, e.g., R, is chloro 
and R, and R, are methyl. In other embodiments, R, is halo, 
R, and R, are alkylsilyloxy, and R, and R, are alkyl, e.g., 
65 R, is chloro, R, and R, are OSi-t-BuMe2, and R, and R, are 
methyl. In one embodiment, the compound has Formula 
(24): 
60 
15 
30 
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In some embodiments, R, is halo, R, and R, are selected 
from hydroxy and alkylsilyloxy, and R, and R, are alkyl, 
e.g., R, is chloro, R, and R, are hydroxy, and R, and R, are 
methyl. In some embodiments, R, is halo, R, and R, are 
alkylsilyloxy, and R, and R, are methyl, e.g., R, is chloro, 
R, and R, are OSi-t-BuMe,, and R, and R, are methyl. In 
some embodiments the compound has Formula (23): 
(24) 
0 
*\@ 10 (23) 
$\O 
: = . -  
$ H  
(IV) 
The invention also features a compound of Formula IV 
8
&R3 
: 
$ H  
(11) 
20 R3 
8 
::-::: 
&R3 +\o 
The invention also features a compound of Formula 11: 
2~ 
%, 
$4 $ H  : R5 : 
"',/ 
. -  
% H  
R, can be independently any of the groups described 
above for R, of Formula I. R, can be independently any of 
the groups described above for R, of Formula I. R, can be 
independently any of the groups described above for R, of 35 
Formula I. R, can be independently hydrido, alkyl, or 
hydroxyalkyl. R, can be independently hydrido, alkyl, or 
hydroxyalkyl. However, when R, is chloro, R, and R, are 
not hydroxy and R, and R, are methyl. R4 R5 
and R, and R, are alkyl. In some embodiments, R, is halo, 
R, and R, are alkylsilyloxy; and R, and R, are alkyl, e.g., 
R, is chloro, R, and R, are OSi-t-BuMe,, and R, and R, are 
methyl. 
In some embodiments, R, is halo, R, and R, are hydroxy, 40 
R, can be independently any of the groups described 
above for R, of Formula I. R, can be independently any of 
The invention also features a compound of Formula 111: 45 the groups described above for R, of Formula I. R, can be 
independently any of the groups described above for R, of 
Formula I. R, can be independently hydrido, alkyl, or 
hydroxyalkyl. R, can be independently hydrido, alkyl, or 
hydroxyalkyl. R, can be independently hydrido, hydroxy, or 
50 acyloxy. R, can be independently alkyl, or arylselenylalkyl. 
In some embodiments, R, is halo, R, and R, are selected 
from hydroxy, alkylsilyloxy, or aralkyloxy, R, and R, are 
alkyl, R, is selected from hydrido, hydroxy, or acyloxy, and 
55 R, is selected from alkyl or arylselenylalkyl, e.g., R, is 
chloro; R, and R, are OSi-t-BuMe,, R, and R, are methyl, 
R, is hydrido, and R, is methyl. In other embodiments, R, 
is chloro, R, and R, are hydroxy, R, and R, are methyl, R, 
6o is hydrido, and R, is methyl. In some embodiments, R, is 
In these compounds, R, can be independently any of the chloro; R, and R3 are arYlalkYloxY; R4 and R5 are methyl, 
groups described above for R1  of Formula I. R, is hydroxy, and R, is arylselenylalkyl. In some 
R, can be independently any of the groups described embodiments, Ri is chloro,; R, and R3 are arYlalkYloxY, and 
above for R, of Formula I. R, can be independently any of R4 and R5 are methyl, R6 is acYloxY, and R7 is arYlselenY- 
the groups described above for R, of Formula I. R, can be 65 1alkYl. In Some embodiments, R, is chloro, R, and R3 are 
independently hydrido, alkyl, or hydroxyalkyl. R, can be arylalkyloxy; R, and R, are methyl, R, is acyloxy, and R, 
independently hydrido, alkyl, or hydroxyalkyl. is methyl. 
(111) 
. -  .  - -
% H  
R4 R5 
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The invention also features a compound of Formula V: 
5 
10 
1s 
R, can be independently any of the groups described 
above for R, of Formula I. R, can be independently any of 
the groups described above for R, of Formula I. R, can be 2o 
independently any of the groups described above for R, of 
Formula I. R, can be independently hydrido, alkyl, or 
hydroxyalkyl. R, is independently hydrido, alkyl, or 
hydroxyalkyl. R, can be hydroxy. R, can be independently 2s 
hydroxy, or alkylsilyloxy. 
6 
O V H  
In some embodiments, R, is halo; R, and R, are aryla- 
lkyloxy; R, and R, are alkyl; R, is hydroxy; and R, is 
R, and R, are OBn; and R, and R, are methyl; R, is 
hydroxy; and R, is OSi-tBuMe,. In some embodiments, R, 
hydroxy; and R, is hydroxy. 
wherein R, is chloro, R, and R, are OSi-tBuMe,. The 
method further comprises isolating compound (18) and 
~~~~~l~ 1, 
from hydroxy and alkylsilyloxy, e.g., Rl is chloro; 30 deprotecting compound (18). The result is a compound of 
is chloro; R~ and R3 are OBn; R4 and R5 are R6 is The invention also features a method of synthesizing (+) 
chloropuupehenone. The method comprises hydrogenating 
compound (19) to form compound (25). 3s 
The inventions also features a method of synthesizing a 
(25) compound of Formula I: 
OSi-t-BuMe2 
4s 
so 
wherein R, is chloro, R, and R, are hydroxy, and R, and R, 
are methyl. The method comprises reacting compound (4) ss 
with compound (3) to form intermediate compound (18). 
60 
65 
Desilylation of compound (25) forms compound (26). 
(26) 
OH 
.OH 
I 
wherein R, is OSi-t-BuMe,, X, is chloro, X, is bromo; 
US 6,727,277 B3 
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Oxidation of compound (26) forms (+) chloropuupe- example, atherosclerosis, hypercholesterolemia, heart 
attack, gangrene, and stroke. The compound can be admin- 
P7) istered orally,  intravascularly,  intraperitoneally,  
subcutaneously, intramuscularly, or topically, and in an 
s amount from about 4 mgkg to about 4 gikg of body weight 
per day. The compound can be administered in a composi- 
tion as described above. The method can be part of a 
treatment regimen comprising a diet low in cholesterol, or as 
part of a treatment regimen that includes administering an 
i o  HMG-CoA reductase inhibitors. The method can be used to 
treat humans. The method can include administering the 
compound for 7 days or more, e.g., for one year or more. 
Unless otherwise defined, all technical and scientific 
terms used herein have the same meaning as commonly 
is understood bv one of ordinarv skill in the art to which this 
henone (27). 
invention pertains. Although methods and materials similar The invention also features a pharmaceutical composition or equivalent to those described herein can be used to comprising a pharmaceutically-acceptable carrier and a practice the invention, suitable methods and materials are compound of Formula 1: 
(1), described below. All publications, patent applications, 
20 patents, and other references mentioned herein are incorpo- 
rated by reference in their entirety. In case of conflict, the 
present specification, including definitions, will control. In 
addition, the materials, methods, and examples are illustra- 
tive only and not intended to be limiting. 
zs The details of one or more embodiments of the invention 
are set forth in the accompanying drawings and the descrip- 
tion below. Other features, objects, and advantages of the 
invention will be apparent from the description and 
drawings, and from the claims. 
The composition 8 can be in the form of a capsule or a liquid absorption FIG. 1 is of a cholesterol graph showing in lymph-cannulated hourly rates of rats. lymphatic Values
emulsion. The composition can in a controlled release are expressed as means+SD, n=5. *Indicates a significant 
formulation, e.g., a dispersion in hydroxypropylmethyl 35 difference between treatments at pe0.05. 
cellulose, or in a formulation suitable for parenteral FIG. 2 is a graph showing hourly rates of lymphatic 
administration, e.g., a lipid emulsion. The composition can absorption of oleic acid in lymph-cannulated rats. Values are 
comprise a diluent such as polyethylene glycol, propylene expressed as means+SD, n=5. *Indicates a significant dif- 
glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame ference between treatments at pe0.05. 
oil, or benzyl alcohol. The pharmaceutically-acceptable car- 40 FIG, 3 is a graph showing percent inhibition of cho~estero~ 
rier material can be lactose, sucrose, starch powder, c e h -  ester transfer protein (CETP) activity in the presence of 
lose esters of alkanoic acids, cellulose alkyl esters, talc, various concentrations of compound 24. The results from 
stearic acid, magnesium stearate, magnesium oxide, sodium two replicates of the assay are shown, 
and calcium salts of phosphoric and sulfuric acids, gelatin, is a graph showing percent inhibition of CETP 
sodium starch glycolate, sodium lauryl sulfate, povidone, 
polyvinylpyrrolidone, or polyvinyl alcohol. 
The invention also features a method for identifying a 
compound that inhibits lymphatic absorption of cholesterol. 
The method comprises administering a known amount of 50 
cholesterol and a compound of claim 1 to a non-human 
mammal, and determining the amount of administered cho- 
nificant decrease in lymphatic cholesterol absorption rela- 
tive to the lymphatic cholesterol absorption of a 55 
corresponding control mammal indicates that the compound 
is effective for inhibiting lymphatic absorption of choles- 
terol. A statistically insignificant change or a statistically 
significant increase in lymphatic cholesterol absorption rela- 
tive to the lymphatic cholesterol absorption of a correspond- 60 
ing control mammal indicates the compound does not inhibit 
lymphatic absorption of cholesterol. The cholesterol and the 
compound can be administered in a lipid emulsion. 
The invention also features a method of treating a 
cholesterol-related condition. The method comprises admin- 65 
istering an effective amount of a compound of Formula I to wherein R, is selected from hydrido, halo, alkyl, alkenyl, 
a mammal. The cholesterol-related condition can be, for alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
OH 
.,@ 
DESCRIPTION OF DRAWINGS 
30 : I H  
FIG, 
acacia gum, sodium microcrystalline 45 activity in the presence of various concentrations of Fer- 
roverdin A, 
DETAILED DESCRIPTION 
Compounds of Formula I 
A class of compounds useful for inhibiting lymphatic 
(1) 
absorption of cholesterol is defined by Formula 1: 
lesterol that is absorbed by the lymph. A statistically sig- 
R3 
<<,@ 
: : (8 $ H  
R4 R5 
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alkoxyalkyl ,  haloalkoxy,  haloalkoxyalkyl ,  aryl ,  Compounds of Formula I1 
N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, 
N-alkyl-N-arylsulfamyl ,  carboxy,  carboxyalkyl ,  
alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, 5 
alkoxycarbonylalkyl,  amido, N-alkylamido, N-N- 
dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, 
N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, lo 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, 
cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, and alkylsilyloxy. 
R, is selected from hydrido, halo, alkyl, alkenyl, alkylyl, 
haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, 
alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N- wherein R, is selected from moieties described above for R, 
dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, 2o groups of Formula I, R, is selected from the moieties 
carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, described above for R, groups of Formula I, R, is selected 
a l k o x y c a r b o n y l ,  a l k o x y c a r b o n y l a l k y l ,  a m i d o ,  from the moieties described above for R, groups of Formula 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, I, R, is selected from hydrido, alkyl, and hydroxyalkyl, and 
N-aW-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl- R, is selected from hydrido, alkyl, and hydroxyalkyl. The 
N-hydroxyamidoalkyl ,  amidoalkyl ,  aminoalkyl ,  25 class of compounds also includes pharmaceutically- 
alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, acceptable salts thereof. 
aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, An exemplary class of compounds includes those com- 
N-alkylamine, NNdialkylamino, acyl, acyloxy, aryloxy, pounds of Formula I1 wherein R, is halo, R, is selected from 
acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, hydroxy and alkylsilyloxy; R, is selected from hydroxy, and 
phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, 3o alkylsilyloxy; R, is selected from hydrido, alkyl and 
and alkylsilyloxy. hydroxyalkyl; and R, is selected from hydrido, alkyl and 
R, is selected from hydrido, halo, alkyl, alkenyl, alkylyl, hydroxyalkyl. 
haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, A family of specific compounds of particular interest 
haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, within Formula 11 consists of compounds and their pharma- 
alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N- 35 ceutically acceptable salts as follows: 
dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, (4aS,6aS,12bS)-2H-9,lO-Bis-(t-butyldime thylsily1oxy)- 
carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, ll-chloro-1,3,4,4a,5,6,6a,l2b-octahydro-4,4,6a,l2b- 
a l k o x y c a r b o n y l ,  a l k o x y c a r b o n y l a l k y l ,  a m i d o ,  tetramethyl-benzo[a]xanthene (19). 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl- 40 
N-hydroxyamidoalkyl ,  amidoalkyl ,  aminoalkyl ,  A third class of compounds is defined by Formula 111: 
alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, 
N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, 45 
phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, 
and alkylsilyloxy. 
R, is selected from hydrido, alkyl, and hydroxyalkyl, and 
R, is selected from hydrido, alkyl, and hydroxyalkyl. The 
class of compounds also includes pharmaceutically- SO 
acceptable salts thereof. 
An exemplary class of compounds includes compounds of 
and alkylsilyloxy, R, is selected from hydroxy and 
alkylsilyloxy, R, is selected from hydrido, alkyl and 55 
hydroxyalkyl; and R, is selected from hydrido, alkyl and 
hydroxy alkyl. 
heteroaryl, alkylsulfonyl, arylsulfonyl, A second class of compounds is defined by Formula 11: 
(11) 
R3 
%, 
: : 
haloalkyl, hydroxyalk l, hydroxy alkoxy, alkoxyalk  :-::: R4 $ H  R5 15 
Compounds of Formula I11 
aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, (111) @yR3 
. -  Formula I, wherein R, is halo, R, is selected from hydroxy 
b H  
R4 R5 
wherein R, is selected from the moieties described above for 
A family of specific compounds of particular interest 
within Formula 1 includes compounds and their pharmaceu- 
R1 groups Of 
described above for R2 groups Of 
'3 R2 is from the moieties 
'3 R3 is 
60 from the moieties described above for R, groups of Formula 
I, R, is selected from hydrido, alkyl and hydroxyalkyl, and 
R, is selected from hydrido, alkyl and hydroxyalkyl. The 
class of compounds also includes pharmaceutically- 
acceptable salts thereof. 
An exemplary class of compounds includes those com- 
pounds of Formula I11 wherein R, is halo, R, is selected 
from hydroxy and alkylsilyloxy; R, is selected from 
tically acceptable salts thereof as follows: 
(4aS,6aR,12bS)-2H-ll-Chl0r0-1,3,4,4a,5,6,6a,12b- 
octahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9, 
10-diol (1); and 
(4aS,6aR,12bS)-2H-9,l0-Bis-(t-butyldimethylsilyloxy)- 65 
ll-chloro-1,3,4,4a,5,6,6a,l2b-octahydro-4,4,6a,l2b- 
tetramethyl-benzo[a]xanthene (18). 
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hydroxy and alkylsilyloxy; R, is selected from hydrido, 
alkyl and hydroxyalkyl; and R, is selected from hydrido, 
alkyl, and hydroxyalkyl. 
A family of specific compounds of particular interest 
within Formula I11 includes compounds and their pharma- 
ceutically acceptable salts as follows: 
(4aS,6aR,12aR,12bS)-2H-9,lO-Bis-(t- 
butyldimethylsilyloxy)-ll-chloro-l,3,4,4a,5,6,6a,12, 
12a,l2b-decahydro-4,4,6a,l2b-tetramethyl-benzo[a] 
xanthene (21); and 
(4aS,6aR,12aR,12bS)-2H-ll-Chloro-1,3,4,4a,5,6,6a,l2, 
12a,l2b-decahydro-4,4,6a,l2b-tetramethyl-benzo[a] 
xanthene-9,lO-diol (22). 
A second family of specific compounds of particular 
interest within Formula I11 includes oxidation products and 
their pharmaceutically acceptable salts as follows: 
(4aS,6aR,12aR,12bS)-2H-ll-Chloro-1,3,4,4a,5,6,6a,9, 
10,12,12a,12b-dodecahydro-4,4,6a,l2b-tetramethyl- 
benzo[a]xanthene-9,1O-dione (23); and 
(4aS,6aR,12aR,12bS)-2H-ll-Chloro-1,3,4,4a,5,6,6a,l2, 
12a,l2b-decahydro-4,4,6a,l2b-tetramethyl-benzo[a] 
xanthene-9,lO-diol (22). 
Compounds of Formula IV 
A fourth class of compounds is defined by Formula I V  
R2 
I 
wherein R, is selected from the moieties described above for 
R, groups of Formula I, R, is selected from the moieties 
described above for R, groups of Formula I, R, is selected 
from the moieties described above for R, groups of Formula 
I, R, is selected from hydrido, alkyl, and hydroxyalkyl, R, 
is selected from hydrido, alkyl, and hydroxyalkyl, R, is 
selected from hydrido, hydroxy, and acyloxy, and R, is 
selected from alkyl and arylselenylalkyl. The class of com- 
pounds also includes pharmaceutically-acceptable salts 
thereof. 
An exemplary class of compounds includes those com- 
pounds of Formula IV wherein R, is halo, R, is selected 
from hydroxy, alkylsilyloxy, and aralkyloxy; R, is selected 
from hydroxy, alkylsilyloxy, and aralkyloxy; R, is selected 
from hydrido, alkyl, and hydroxyalkyl; R, is selected from 
hydrido, alkyl, and hydroxyalkyl; R, is selected from 
hydrido, hydroxy, and acyloxy; and R, is selected from alkyl 
and arylselenylalkyl. 
A family of specific compounds of particular interest 
within Formula IV includes the following compounds and 
their pharmaceutically acceptable salts as follows: 
(4aS,6aS,12aR,12bS)-2H-9,lO-Bis-(t- 
butyldimethylsilyloxy)-ll-chloro-l,3,4,4a,5,6,6a,12, 
12a,l2b-decahydro-4,4,6a,l2b-tetramethyl-benzo[a] 
xanthene (25); (4aS,6aS,12aR,12bS)-2H-ll-Chloro-l, 
3,4,4a,5,6,6a,12,12a,l2b-decahydro-4,4,6a,l2b- 
S 
10 
1s 
20 
2s 
30 
3s 
40 
4s 
so 
5s 
60 
65 
12 
tetramethyl-benzo[a]xanthene-9,lO-diol (26); (4aS, 
6aR,12aS,12bS)-2H-9,lO-Bis-benzyloxy)-ll-chloro- 
hydroxy-6a-(phenylselenylmethyl)-1,3,4,4a,5,6,6a,l2, 
12a,l2b-decahydro-4,4,12b-trimethyl-benzo[a] 
xanthene (40); (4aS,6aR,12aS,12bS)-2H-12-Acetoxy- 
9 , l O  - b i s  -( b e n z y l o  x y )  - 11 - c h l o  r o - 6 a - 
(phenylselenylmethyl)-1,3,4,4a,5,6,6a,12,12a,l2b- 
decahydro-4,4,12b-trimethyl-benzo[a]xanthene (41); 
and (4aS,6aS,12aS,12bS)-2H-12-Acetoxy-9,lO-bis- 
(benzyloxy)-ll-chloro-1,3,4,4a,5,6,6a,12,12a,l2b- 
decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene 
(42). 
Compounds of Formula V 
A fifth class of compounds is defined by Formula V 
wherein R, is selected from the moieties described above for 
R, groups of Formula I, R, is selected from the moieties 
described above for R, groups of Formula I, R, is selected 
from the moieties described above for R, groups of Formula 
I, R, is selected from hydrido, alkyl, and hydroxyalkyl, R, 
is selected from hydrido, alkyl, and hydroxyalkyl, R, is 
hydroxy, and R, is selected from hydroxy and alkylsilyloxy. 
The class of compounds also includes pharmaceutically- 
acceptable salts thereof. 
An exemplary class of compounds includes those com- 
pounds of Formula V wherein R, is halo; R, is selected from 
hydroxy, alkylsilyloxy and aralkyloxy; R, is selected from 
hydroxy, alkylsilyloxy, and aralkyloxy; R, is selected from 
hydrido, alkyl, and hydroxyalkyl; R, is selected from 
hydrido, alkyl, and hydroxyalkyl; R, is hydroxy; and R, is 
selected from hydroxy and alkylsilyloxy. 
A family of specific compounds of particular interest 
within Formula V includes the following compounds and 
their pharmaceutically acceptable salts as follows: (4aS, 
8aS)-1-{[2-chloro-3,4-dibenzyloxy-6-(t- 
but  y ldim e t h y ls i l  y lo  x y ) ]p he n y 1 hydroxy m e t h y 1 } -2  - 
methylene-5,5,8a-trimethyldecahydronaphthalene (37); and 
(4aS,8aS)-1-{ [2-chloro-3,4-dibenzyloxy-6-hydroxy] 
phenylhydroxymethyl]-2-methylene-5,5,8a- 
trimethyldecahydronaphthalene (38). 
The term “alkyl” embraces linear or branched saturated 
aliphatic radicals having one to about twenty carbon atoms 
or, preferably, one to about twelve carbon atoms. More 
preferred alkyl radicals are “lower alkyl” radicals having 
one to about ten carbon atoms. Most preferred are lower 
alkyl radicals having one to about four carbon atoms. 
Examples of such radicals include methyl, ethyl, n-propyl, 
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 
iso-amyl, hexyl, octyl and the like. The term alkyl also 
includes cycloalkyl (alicyclic) groups (cyclopropyl, 
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl sub- 
stituted cycloalkyl groups, and cycloalkyl substituted alkyl 
groups. 
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The term alkyl includes both “unsubstituted alkyls” and defined above. Specifically embraced are monohaloalkyl, 
“substituted alkyls”, the latter of which refers to alkyl dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl 
moieties having substituents replacing a hydrogen on one or radical, for one example, may have either a bromo, chloro or 
more carbons of the hydrocarbon backbone. Such substitu- a fluoro atom within the radical. Dihalo radicals may have 
ents can include, for example, alkenyl, alkynyl, halogen, s two or more of the same halo atoms or a combination of 
h y d r o x y  1, a lk  y l c  ar  b o n y l o  x y, ar  y l c  ar  b o n y l o  x y, different halo radicals and polyhaloalkyl radicals may have 
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, more than two of the same halo atoms or a combination of 
a l k  y l c  a rb  o n y 1, ar  y l c  a rb  o n y 1, a l k o  x y c  a rb  o n y 1, different halo radicals. The term “hydroxyalkyl” embraces 
aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, linear or branched alkyl radicals having one to about ten 
alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, i o  carbon atoms any one of which may be substituted with one 
phosphinato, cyano, amino (including alkyl amino, or more hydroxyl radicals. The terms “alkoxy” and “alkoxy- 
dialkylamino, arylamino, diarylamino, and alkylarylamino), alkyl” embrace linear or branched oxy-containing radicals 
a c y  1 a m i  n o  ( i n c l u d i n g  a l k  y l c  a r  b o n y 1 a m  i n  0 ,  each having alkyl portions of one to about ten carbon atoms, 
arylcarbonylamino, carbamoyl and ureido), amidino, imino, such as methoxy radical. The term “alkoxyalkyl” also 
sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, is embraces alkyl radicals having two or more alkoxy radicals 
alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, attached to the alkyl radical, that is, to form monoalkoxy- 
trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an alkyl and dialkoxyalkyl radicals. The “alkoxy” or “alkoxy- 
aromatic or heteroaromatic moiety. Cycloalkyls can be fur- alkyl” radicals may be further substituted with one or more 
ther substituted, e.g., with the substituents described above. halo atoms, such as fluoro chloro or bromo to provide 
An “arylalkyl” moiety is an alkyl substituted with an aryl 20 “haloalkoxy” or “haloalkoxyalkyl” radicals. Examples of 
(e.g., phenylmethyl (benzyl)). The term “n-alkyl” means a “alkoxy” radicals include methoxy butoxy and trifluo- 
straight chain (i.e. unbranched) unsubstituted alkyl group. romethoxy. The term “aryl”, alone or in combination, means 
The term “alkenyl” includes unsaturated aliphatic groups a carbocyclic aromatic system containing one, two or three 
analogous in length and possible substitution to the alkyls rings wherein such rings may be attached together in a 
described above, but that contain at least one double bond zs pendent manner or may be fused. The term “aryl” embraces 
and must contain at least two carbon atoms. For example, the a r o m a t i c  r a d i c a l s  s u c h  a s  p he n y 1, nap  h th y 1, 
term “alkenyl” includes straight-chain alkenyl groups (e.g., tetrahydronapthyl, indane and biphenyl. The term “hetero- 
ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, cyclic” embraces saturated, partially saturated and unsatur- 
octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl ated heteroatom-containing ring-shaped radicals, where the 
groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, 30 heteroatoms may be selected from nitrogen, sulfur and 
cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), oxygen. Examples of saturated heterocyclic radicals include 
alkyl or alkenyl substituted cycloalkenyl groups, and pyrrolidyl and morpholinyl. The term “heteroaryl” embraces 
cycloalkyl or cycloalkenyl substituted alkenyl groups. unsaturated heterocyclic radicals. Examples of unsaturated 
The term alkenyl includes both “unsubstituted alkenyls” heterocyclic radicals, also termed “heteroaryl” radicals 
and “substituted alkenyls”, the latter of which refers to 3s include thienyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, 
alkenyl moieties having substituents replacing a hydrogen pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyra- 
on one or more carbons of the hydrocarbon backbone. Such nyl and tetrazolyl. The term also embraces radicals where 
substituents can include, for example, alkyl groups, alkynyl heterocyclic radicals are fused with aryl radicals. Examples 
groups ,  ha logens ,  hydroxyl ,  a lkylcarbonyloxy,  of such fused bicyclic radicals include benzofuran, 
arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, 40 benzothiophene, and the like. The term “sulfonyl”, whether 
carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, used alone or linked to other terms such as alkylsulfonyl, 
aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, denotes  respectively divalent radicals -S Oz-. 
alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, “Alkylsulfonyl”, embraces alkyl radicals attached to a sul- 
phosphinato, cyano, amino (including alkyl amino, fonyl radical, where alkyl is defined as above. The term 
dialkylamino, arylamino, diarylamino, and alkylarylamino), 4s “arylsulfonyl” embraces sulfonyl radicals substituted with 
a c y  1 a m  i n o  an aryl radical. The terms “sulfamyl” or “sulfonamidyl”, 
arylcarbonylamino, carbamoyl andureido), amidino, imino, w h e t h e r  a l o n e  o r  u s e d  w i t h  t e r m s  s u c h  a s  
sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, “ N - a l k y l s u l f a m y l ” ,  “ N - a r y l s u l f a m y l ” ,  “ N , N -  
alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, dialkylsulfamyl” and “N-alkyl-N-arylsulfamyl”, denotes a 
trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an SO sulfonyl radical substituted with an amine radical, forming 
aromatic or heteroaromatic moiety. a sulfonamide ( S O z N H z ) .  The terms “N-alkylsulfamyl” 
The term “alkynyl” includes unsaturated aliphatic groups and “N,N-dialkylsulfamyl” denote sulfamyl radicals 
analogous in length and possible substitution to the alkyls substituted, respectively, with one alkyl radical, a cycloalkyl 
described above, but which contain at least one triple bond ring, or two alkyl radicals. The terms “N-arylsulfamyl” and 
and two carbon atoms. For example, the term “alkynyl” ss “N-alkyl-N-arylsulfamyl” denote sulfamyl radicals 
includes straight-chain alkynyl groups (e.g., ethynyl, substituted, respectively, with one aryl radical, and one alkyl 
propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, and one aryl radical. The terms “carboxy” or “carboxyl”, 
nonynyl, decynyl, etc.), branched-chain alkynyl groups, and whether used alone or with other terms, such as 
cycloalkyl or cycloalkenyl substituted alkynyl groups. “carboxyalkyl”, denotes -CO,H. The term “carboxyalkyl” 
The term “hydrido” denotes a single hydrogen atom (H). 60 embraces radicals having a carboxy radical as defined above, 
This hydrido radical may be attached, for example, to an attached to an alkyl radical. The term “carbonyl”, whether 
oxygen atom to form a hydroxyl radical or two hydrido used alone or with other terms, such as “alkylcarbonyl”, 
radicals may be attached to a carbon atom to form a denotes +C=O)-. The term “alkylcarbonyl” embraces 
methylene (-CHz-) radical. The term “halo” means halo- radicals having a carbonyl radical substituted with an alkyl 
gens such as fluorine, chlorine, bromine or iodine atoms. 65 radical. An example of an “alkylcarbonyl” radical is CH,- 
The term “haloalkyl” embraces radicals wherein any one or (C=O)-. The term “alkylcarbonylalkyl”, denotes an alkyl 
more of the alkyl carbon atoms is substituted with halo as radical substituted with an “alkylcarbonyl” radical. The term 
( i  n c l u  d i n  g a 1 k y 1 c a r b  o n y 1 a m i n  0 ,  
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“alkoxycarbonyl” means a radical containing an alkoxy lkyl” denotes an alkyl radical substitute with a selenylaryl 
radical, as defined above, attached via an oxygen atom to a group. An example of an “arylselenylalkyl” radical is 
carbonyl (C=O) radical. Examples of such “alkoxycarbo- -CH,SePh. 
nyl” radicals include (CH,),CO-C(=O)- and -(O=) Also included in the family of compounds of Formulae 
C-OCH,. The term “alkoxycarbonylalkyl” embraces radi- s I-V are pharmaceutically-acceptable salts thereof. The term 
cals having “alkoxycarbonyl”, as defined above substituted “pharmaceutically-acceptable salts” embraces salts com- 
to an alkyl radical. Examples of such “alkoxycarbonylalkyl” monly used to form alkali metal salts and to form addition 
radicals include (CH3),C0C(=0)(CH,),- and +CH,), salts of free acids or free bases. Suitable pharmaceutically- 
(=O)COCH,. The term “amido” when used by itself or with acceptable acid addition salts of compounds of Formula I 
other terms such as “amidoalkyl”, “N-monoalkylamido”, i o  may be prepared from an inorganic acid or from an organic 
“N-monoarylamido”, “N,N-dialkylamido”, “N-alkyl-N- acid. Examples of such inorganic acids are hydrochloric, 
arylamido”, “N-alkyl-N-hydroxyamido” and “N-alkyl-N- hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phos- 
hydroxyamidoalkyl”, embraces a carbonyl radical substi- phoric acid. Appropriate organic acids may be selected from 
tuted with an amino radical. The terms “N-alkylamido” and aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, 
“N,N-dialkylamido” denote amido groups which have been is carboxylic and sulfonic classes of organic acids, example of 
substituted with one alkyl radical and with two alkyl which are formic, acetic, propionic, succinic, glycolic, 
radicals, respectively. The terms “N-monoarylamido” and gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, 
“N-alkyl-N-arylamido” denote amido radicals substituted, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, 
respectively, with one aryl radical, and one alkyl and one anthranilic, mesylic, salicyclic, p-hydroxybenzoic, 
aryl radical. The term “N-alkyl-N-hydroxyamido” embraces 20 p h e  n y 1 a c e t i c  , m a n d  e l i  c , e m b o n i c  ( p a m  o i c )  , 
amido radicals substituted with a hydroxyl radical and with methanesulfonic, ethanesulfonic, benzenesulfonic, 
an alkyl radical. The term “N-alkyl-N-hydroxyamidoalkyl” pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, 
embraces alkyl radicals substituted with an N-alkyl-N- sulfanilic, cyclohexylaminosulfonic, stearic, algenic, 
hydroxyamido radical. The term “amidoalkyl” embraces hydroxybutyric, salicyclic, galactaric and galacturonic acid. 
alkyl radicals substituted with amido radicals. The term zs Suitable pharmaceutically-acceptable base addition salts of 
“aminoalkyl” embraces alkyl radicals substituted with compounds of Formula I include metallic salts made from 
amine radicals. The term “alkylaminoalkyl” embraces ami- aluminum, calcium, lithium, magnesium, potassium, sodium 
noalkyl radicals having the nitrogen atom substituted with and  z i n c  o r  o r g a n i c  s a l t s  m a d e  f r o m  N , N ’ -  
an alkyl radical. The term “amidino” denotes an dibenzylethylenediamine, chloroprocaine, choline, 
-C(=NH)-NH, radical. The term “cyanoamidino” 30 d i e t  h ano  1 a m i n e ,  e t  h y le  ne d i  a min  e ,  me g l u m  i n e  
denotes an -C(=N-CN)-NH, radical. The term “het- (N-methylglucamine) and procaine. All of these salts may be 
erocycloalkyl” embraces heterocyclic-substituted alkyl radi- prepared by conventional means from the corresponding 
cals such as pyridylmethyl and thienylmethyl. The term compound of Formula I, 11, 111, IV, or V by reacting, for 
“aralkyl” embraces aryl-substituted alkyl radicals such as example, the appropriate acid or base with the compound of 
benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and 3s Formula I, 11, 111, IV, or V. 
diphenethyl. The terms benzyl and phenylmethyl are inter- Pharmaceutical Compositions 
changeable. The term “cycloalkyl” embraces radicals having The present invention includes a pharmaceutical compo- 
three to ten carbon atoms, such as cyclopropyl cyclobutyl, sition for inhibiting lymphatic absorption of cholesterol, 
cyclopentyl, cyclohexyl and cycloheptyl. The term comprising a therapeutically-effective amount of a com- 
“cvcloalkenvl” embraces unsaturated radicals having three 40 aound of Formula I in association with at least one v 
to ten carbon atoms, such as cylopropenyl, cyclobutenyl 
cyclopentenyl cyclohexenyl and cycloheptenyl. The term 
“alkylthio” embraces radicals containing a linear or 
branched alkyl radical, of one to ten carbon atoms, attached 
to a divalent sulfur atom. The term “arylsulfenyl” embraces 
aryl radicals attached to a divalent sulfur atom ( S A r )  An 
example of “alkylthio” is methylthio, (CH,S-). The term 
“alkylsulfinyl” embraces radicals containing a linear or 
branched alkyl radical, of one to ten carbon atoms, attached 
to a divalent -S(=O)- atom. The term “arvlsulfinvl” 
pharmaceutically-acceptable carrier, adjuvant or diluent. 
A pharmaceutical composition comprises one or more 
compounds of Formulae I-V in association with one or more 
non-toxic, pharmaceutically acceptable carriers and/or dilu- 
4s ents and/or adjuvants (collectively referred to herein as 
“carrier” materials) and, if desired, other active ingredients. 
A compound of the present invention may be administered 
by any suitable route, preferably in the form of a pharma- 
ceutical composition adapted to such a route, and in a dose 
SO effective for the treatment intended. A comaound mav. for 
\ ,  ,l 
embraces aryl radicals attached to a divalent -S(=O)- example,  be administered orally, intravascularly, 
atom (e.g., -S=OAr). The terms “N-alkylamino” and intraperitoneally, subcutaneously, intramuscularly or topi- 
“N,N-dialkylamino” denote amine groups which have been cally. 
substituted with one alkyl radical and with two alkyl For oral administration, a pharmaceutical composition 
radicals, respectively. The term “acyl”, whether used alone, ss may be in the form of, for example, a tablet, capsule, 
or within a term such as “acylamino”, denotes a radical emulsion, suspension or solution. A pharmaceutical compo- 
provided by the residue after removal of hydroxyl from an sition is preferably made in the form of a dosage unit 
organic acid. The term “acylamino” embraces an amine containing a particular amount of the active ingredient. 
radical substituted with an acyl group. An examples of an Examples of such dosage units are tablets or capsules. The 
“acylamino” radical is acetylamine (CH,C(=O)-NH-). 60 active ingredient may also be administered by injection as a 
The term “aryloxy” denotes a radical provided by the composition wherein, for example, saline, dextrose or water 
residue after removal of hydrido from a hydroxy-substituted may be used as a suitable carrier. 
aryl moiety (e.g., phenol). The term “alkylsilyl” denotes a The amount of therapeutically active compound that is 
silyl radical substituted with an alkyl group. The term administered and the dosage regimen for treating a disease 
“alkylsilyloxy” denotes a silyloxy radical (-OSi-) sub- 65 condition with the compounds and/or compositions of this 
stituted with an alkyl group. An example of an “alkylsily- invention depends on a variety of factors, including the age, 
loxy” radical is -0Si-t-BuMe,.  The term “arylselenyla- weight, sex and medical condition of the subject, the sever- 
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ity of the disease, the route and frequency of administration, 
and the particular compound employed, and thus may vary 
widely. 
If administered per os, the compounds may be admixed 
with lactose, sucrose, starch powder, cellulose esters of 
alkanoic acids, cellulose alkyl esters, talc, stearic acid, 
magnesium stearate, magnesium oxide, sodium and calcium 
salts of phosphoric and sulfuric acids, gelatin, acacia gum, 
sodium alginate, microcrystalline cellulose, sodium starch 
g l y c o l a t e ,  s o d i u m  l a u r y l  s u l f a t e ,  p o v i d o n e ,  
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then 
tableted or encapsulated for convenient administration. Cap- 
sule or tablet shells can contain, e.g., gelatin, titanium 
dioxide, and dyes. Such capsules or tablets may contain a 
controlled-release formulation as may be provided in a 
dispersion of active compound in hydroxypropylmethyl 
cellulose. Formulations for parenteral administration may be 
in the form of aqueous or non-aqueous isotonic sterile 
injection solutions or suspensions. These solutions and sus- 
pensions may be prepared from sterile powders or granules 
having one or more of the carriers or diluents mentioned for 
use in the formulations for oral administration. The com- 
pounds may be dissolved in water, polyethylene glycol, 
propylene glycol, ethanol, corn oil, cottonseed oil, peanut 
oil, sesame oil, benzyl alcohol, sodium chloride, and/or 
various buffers. Other adjuvants and modes of administra- 
tion are well and widely known in the pharmaceutical art. 
Methods 
Compounds of Formula I and related compounds can be 
utilized in the treatment of cholesterol-related conditions in 
mammals, including humans, dogs and cats. Cholesterol- 
related conditions include, for example, atherosclerosis, 
hypercholesterolemia, heart attack, stroke, and gangrene of 
the extremities. A method of treatment includes administer- 
ing an effective amount of a compound of Formula I. The 
compound can be administered as a pharmaceutical 
composition, as described above. Acompound of the present 
invention may be administered by any suitable route, typi- 
cally in the form of a pharmaceutical composition adapted to 
such a route, and in a dose effective for the treatment 
intended. A compound may, for example, be administered 
orally, intravascularly, intraperitoneally, subcutaneously, 
intramuscularly or topically. 
The amount of compound that is administered and the 
dosage regimen for treating a disease condition with the 
compounds and/or compositions of this invention depends 
on a variety of factors and can be determined by an attending 
physician. These factors include the age, body weight, sex 
and medical condition of the subject, the severity of the 
disease, the route and frequency of administration, the 
particular compound employed, health status, diet, other 
medications, and other relevant clinical factors. The amount 
of compound administered can range from about 4 m a g  
body weight per day to about 4 g/kg of body weight per day. 
For example, a compound can be administered at a daily 
dosage of 5 mg/kg, 10 mg/kg, 100 mg/kg, 250 mg/kg, 1000 
mg/kg, 1500 mg/kg, 2000 mg/kg, or 3000 mg/kg. The daily 
dosage can be administered once per day, twice per day, 
three times per day, or four or more times per day. Variations 
in these dosage levels can be adjusted using standard empiri- 
cal routines for optimization. 
The concentration of a compound of the present invention 
effective to treat a cholesterol-related condition in a mammal 
may vary, depending on a number of factors, including the 
preferred dosage of the compound to be administered, the 
chemical characteristics of the compounds employed, the 
formulation of the compound excipients and the route of 
S 
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administration. The optimal dosage of a pharmaceutical 
composition to be administered may also depend on such 
variables as the overall health status of the particular patient 
and the relative biological efficacy of the compound 
selected. The amount and dosage regimen effective for 
treating a cholesterol-related condition in a mammal can be 
determined by, e.g., measuring cholesterol levels prior to the 
start of treatment and at various times after treatment has 
commenced. Assays for the quantitation of cholesterol are 
known, including assays for the level of cholesterol in blood 
or in lymph. Administration of an effective amount results in 
a decrease in lymphatic absorption of cholesterol that is 
statistically significant at a p50.05 with an appropriate 
parametric or non-parametric statistic, e.g., Chi-square test, 
Student’s t-test, Mann-Whitney test, or F-test. In some 
embodiments, a difference in cholesterol level is statistically 
significant at pe0.01, pe0.005, or peO.001. 
A compound of the present invention can be administered 
as a single dose or can be administered for a period of from 
one day to many years, e.g., for 3 days or more, for 7 days 
or more, for 14 days or more, for 30 days or more, for one 
year or more, or for 3 years or more. The duration of the 
administration period depends upon, e.g., the daily dosage, 
the type of cholesterol-related condition and the patient’s 
response to the compound. 
A compound of the present invention can be administered 
in conjunction with a diet low in cholesterol as part of a 
cholesterol lowering treatment regime. A compound of the 
present invention also can be administered in conjunction 
with drugs such as Lovastatin (sold as Mevacor from Merck 
Co.), Mevalotin (from Sankyo Co., Japan), and analogs 
thereof (e.g., compounds sold under the trade names 
Sivastatin, Mevastatin, and Pravastatin), to lower total cho- 
lesterol levels and to prevent and treat cholesterol-related 
conditions, e.g., hypercholesterolemia. A compound of the 
invention also can be administered in conjunction with 
XenicalB,, a prescription medication offered for use in 
weight loss regimens. 
Compounds of Formulae I-V also can be tested for their 
effect on lymphatic absorption of dietary cholesterol. Meth- 
ods for measuring lymphatic absorption of cholesterol in 
vivo are known. A suitable in vivo method is described in 
Loest, et al., J. Nutr. 132: 1282-1288 (2002). 
Typically, a method of measuring inhibition of cholesterol 
absorption in vivo involves administering a predetermined 
amount of cholesterol and a test compound of Formulae I-V 
to the intestine of a mammal. Typically, the animal is a fasted 
mammal. The cholesterol and test compound can be admin- 
istered in a lipid emulsion into the duodenum of the mammal 
over a period of a few hours. Suitable non-human mammals 
include rats, mice, guinea pigs, and hamsters. The amount of 
administered cholesterol that appears in the mesenteric 
lymph of the mammal is determined at various times during 
and after administration, typically at hourly intervals. The 
amount of cholesterol present in the lymph is compared to 
the amount present in a control animal that has had choles- 
terol but no test compound administered. If the amount of 
cholesterol appearing in the lymph of the test animal is 
statistically significantly less than the amount of cholesterol 
in the lymph of the control animal, it is concluded that the 
compound can inhibit intestinal absorption of cholesterol. 
General Synthetic Procedures 
The compounds of the invention can be synthesized 
according to the procedures of Schemes 1-6, wherein the 
R,-R, substituents are as defined for Formulae I-V, above, 
except where further noted. 
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Scheme 1 shows the synthesis of enantiopure A-B frag- 
ment 3 from commercially available 3aR-(+)-sclareolide 5 
(purchased from Aldrich Chemical Company). Deprotona- 
tion of optically pure lactone 5 with LDA (lithium 
diisopropylamide) in THF at -78" C., followed by treatment 5 
with M o 0 5 .  p y r i d i n e .  H M PA1 c o m p 1 ex g av e two 
diasteromers, 6 (65.6% yield) and 7 (12.4% yield)) (which 
were separated by silica gel chromatography), along with 
20% recovery of starting sclareolide 5. Treatment of a 
mixture of 6 and 7 with lithium aluminum hydride in THF lo 
at room temperature gave triol 8 (70% yield) and lactol 9 
(30% yield). Oxidative cleavage of 8 with lead tetraacetate 
in benzene at 25" C. provided an 90% yield of 10, and 
oxidative cleavage of 9 under similar conditions gave an 
85% yield of 11. Dehydration of alcohol 10  with 
p-toluenesulfonic acid in refluxing toluene for 2 h gave a 
78% yield of enal 3. Basic hydrolysis of the formyl ester 
group of 11 with potassium carbonate in methanol at 0" C. 
provided a 92% yield of 10, which was converted into 3, as 
described above. The preparation of compound 3 from 2o 
(-)-sclareol using a different synthetic method has been 
reported previously (Reeves, P. G. (1996). 
Schemel 
25 
LDA, THF 
Mo05(pyr.) HMPA 
-78" C. 
* 
30 
35 3aR-(+)-Sclareolide (5) 
8 
LiAlH4, 
THF 
25" c .  
40 
6 7 
(separated) 
(65.6% yield) (12.4% yield) 45 
OH 
+ 
HO i p "  q5 B H  
Pb(OAc)4 
benzene 
25" C., 4 h 
(90% yield) 
* 
8 9 
(70% yield) (30% yield) 
p-TsOH 
toluene 
reflux, 2 h 
(78% yield) 
* 
-continued 
3 
O V H  
K2co3 
MeOH 
* 10 
benzene OCHO OoC. 
25" C., 4 h 
(85% yield) 
(92% yield) 
9 
B H  
11 
Scheme 2 shows the preparation of D-ring fragment 4 
starting from 3-chlorovanillin 12, derived from the chlori- 
nation of vanillin with chlorine in acetic acid (85% yield), 
according to the procedure of Hann et al. (J. Am. Chem. 
SOC., 1927, 49, 535-7). Demethylation of 12 with BBr, in 
CH,Cl, (94% yield) followed by protection of the diol with 
t - b u t y l d i m e t h y l s i l y l  c h l o r i d e ,  t r i e t h y l a m i n e ,  
4-dimethylaminopyridine (DMAP) gave aldehyde 13 (93% 
yield) (Jong, T. T.; Williard, P. G.; Ponvoll, J. P., J. Org. 
Chem., 1984, 49, 735-6). Baeyer-Villiger oxidation of 13 
with m-chloroperbenzoic acid (MCPBA) in methylene chlo- 
ride (70% yield) followed by basic hydrolysis with potas- 
sium carbonate (90% yield) and silylation of the resulting 
phenol with t-butyldimethylsilyl chloride (83% yield) pro- 
vided trisilyl ether 14. Selective C4 (less hindered site 
c o m p a r e d  w i t h  C6) b r o m i n a t i o n  of 1 4  w i t h  
N-bromosuccinimide (NBS) in N,N-dimethylformamide 
(DMF) at 25" C. gave an 67% yield of 4 as the sole product; 
no C6 isomer 15 was isolated. Interestingly, when the 
bromination was carried out at 50" C., a 2: l  ratio of 15 and 
4 was obtained. 
Alternatively, compound 4 was also obtained from the 
bromination of phenol 16 (obtained from 13 with MCPBA 
and potassium carbonate) with N-bromosuccinimide (NBS) 
in DMF to give a 70% yield of bromide 17. Silylation of 17 
with t-butyldimethylsilyl chloride afforded a 99% yield of 4. 
Schrmr? 
- 
HO Et3N, DMAP 
(93% yield) 
c1 
I' 
1. MCPBA 
Ro-cHo (70% yield) * 
2. K2CO3 
(90% yield) 
3. t-BuMe2SiC1 RO 
I (83% yield) 
c1 
13: R = t-BuMe2Si 10 
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-continued -continued 
NBS 
(67% DMF, yield) r.t. * "qoH 25:day- 
RO RO (70% yield) 
c1 c1 
14 16: R = t-BuMezSi 
R = t-BuMezSi 10 R O q O H  t-BuE;SiCl 
DMAP 
* 4  
RO Br (99% yield) 
c1 
17: R = t-BuMezSi 
RO oqoR c1 Br 
RO o*oR 
C1 
15 
When the NBS reaction was 
carried out at 50" C., a 2:l 
ratio of 15 & 4 was obtained 
t-BuMezSiO q ( 3 r - t - B u M e z  
t-BuMezSiO 
Scheme 3 shows a procedure for preparing compounds 
embraced by Formulae I and I1 from enantiopure A-B 
fragment 3 and D-ring fragment 4. Treatment of 4 with 2 
25 equiv of t-BuLi in diethyl ether at -78" C. followed by 
aldehyde 3 afforded a mixture of two stereoisomers at C6a, 
18 (45% yield) and 19 (9.1% yield). Removal of the silyl 
ether protecting groups of 18 and 19 separately gave com- 
pound 1(82% yield) and compound 2 (81.4% yield), respec- 
30 tively. Spectral data of compound 2 was identical with those 
reported (Nasu, S. S.; Yeung, B. K. S.; Hamann, M. T.; 
Scheuer, P. J.; Kelly-Borges, M.; Goins, K., J. Org. Chem. 
1995, 60, 7290-7292). 
2 eq t-BuLi 
ether, -78" C.; 
3 
* 
OSi-t-BuMez 
I 
+ 
c1 
4 
18 
(45% yield) 
OSi-t-BuMez 
OSi-t-BuMez 
19 
(9.1% yield) 
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-continued 
n-Bu4NF 
THF, 25" C. 
(82% yield) 
18 * 
n-Bu4NF 
THF, 25" C. 
(81.4% yield) 
19 * 
2 
OH 
I 
OH 
Scheme 4 shows the preparation of compounds embraced 35 
by Formulae 111, IV, and VI. Selective hydrogenation of 18 
with 1 atmosphere of hydrogen in the presence of palladium/ 
carbon in ethanol gave a 99% yield of tetracyclic pyran 21 
as a single diastereomer (Scheme 4a). Removal of the 
silyloxy protecting group of 21 with tetra-n-butylammonium 40 
fluoride in THF afforded an 83% yield of diol 22. 
Oxidation of diol 22 with pyridinium dichromate (PDC) 
in dichloromethane gave a mixture of quinones 23 and 24 in 
a ratio of 6:l .  Quinone structures 23 and 24 were assigned 
based on 'H NMR spectrum. 
Similarly, hydrogenation of 19 with 1 atmosphere of 
hydrogen and palladiumicarbon (90% yield) followed by 
desilylation with tetra-n-butylammonium fluoride in THF 
(31% yield) and oxidation with pyridinium dichromate 50 
afforded (+)-chloropuupehenone (27) in 50% yield. 
45 
OSi-t-BuMe2 
I 
Hfld-C 
EtOH, 25" C. 
(99% yield) 
* 
55 
60 
65 
OSi-t-BuMe2 
I 
OSi-t-BuMe? 
20B 
-continued 
OSi-t-BuMe2 
I 
OSi-t-BuMe2 
n-Bu4NF 
THF, 25" C. 
(83% yield) 
* 
21 
OH 
pyridinium 
dichromate 
18 22 
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-continued Schemes 5 and 6 show a procedure for preparation of 
C6a-S tetracyclic pyran compounds embraced by Formulae 
IV and V. Scheme 5 shows the preparation of (1R,4aS,6aS)- 
2 , 5 , 5 , 8 a - t e t r a m e t h y l - l , 4 , 4 a , 5 , 6 , 7 , 8 , 8 a -  
octahydronaphthalene-1-carboxaldehyde (33) and (1R,4aS, 
6aS)-2-Methylene-5,5,8a-trimethyl-l,2,3,4,4a,5,6,7,8,8a,- 
decahydronaphthalene-1-carboxaldehyde (35). Reduction of 
aldehyde 10 with lithium aluminum hydride in diethyl ether 
at 0" C. produced a 97% yield of diol 28. Silylation of the 
l e s s  h i n d e r e d  p r i m a r y  a l c o h o l  of  2 8  w i t h  
t-butyldimethylsilyl chloride and imidazole in DMF gave 
alcohol 29 (98% yield). Elimination of 29 with methane- 
23 24 sulfonyl chloride (MsC1) and triethylamine in dichlo- 
romethane afforded a mixture of alkenes 30 and 31 (1:l; 
90% yield), which were separated by silica gel column 
OSi-t-BuMe2 chromatography. Desilylation of 30  with tetra-n- 
butylammonium fluoride in THF (88% yield) followed by 
2o oxidation with Dess-Martin Periodinane in dichloromethane 
provided aldehyde 33 (67% yield). Similarly, silyl ether 31 
was converted to aldehyde 35 under similar reaction condi- 
tions. 
& + &  .,o *+\o 
.& . -  I O  (31% yield) 35 8 * 
. -  . -  . -  . -  
% H  
% '5. H 
(6:l) 
OSi-t-BuMe2 
Hfld-C 
EtOH, 25" C. 
(90% yield) 
SchemeS 25 . -  .  
' S H  
19 
LiA1H4 
ether 
0" c .  
"J,, 
n-Bu4NF 30&0H \ f i  
(97% yield) * 
OSi-t-BuMe2 
OSi-t-BuMe2 
THF, 25" C. 
10 
. -   
' S H  
0 
25 
OH 
&OH I O  
. -  .  
' S H  
0 
pyridinium 
dichromate 
40 
CHzClz, 
25" c .  
(50% yield) 
50 
26 
OH 
I 
28 
45 
t-BuMezSiCl 
imidazole 
DMF 
(98% yield) 
* 
,0Si-t-BuMe2 
MeS02C1 
Et3N 
CH2C12 
(90% yield) 
* 
I H  
Chloropuupehenone (1:l; separated) 
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-continued 
28 
n-Bu4NF 
THF 
(88% yield) 
30 * 
THF * 
31 
32 
n-Bu4NF 
(-88% yield) 
34 
Dess-Martin 
periodinane 
(67% yield) 
* 
1.1 eq t-BuLi 
ether, -78" C.; 
(62% yield) BnO Br 
5 
33 
Dess-Martin 
periodinane 
(-67% yield) 
* 
3 s  
c1 
36 
Bn = CH2Ph 
TBS = t-BuMe2Si 
10 
OBn 
I 
n-Bu4NF 
THF 
20 
- 
(63% yield) 
37 
OBn 
39 
&OBn 
nyl opposite carbocation re gentface from approaches of C12a the alkyl opposite C6a group exo side and ouble of C7 thoxygen sel ium bond attacks from ion the to @OBn 
Referring to synthetic Scheme 6, Bromide 36 was syn- 
thesized from the dibenzylation of 3,4-dihydroxy-5- 
chlorobenzaldehyde (see Scheme 2) with NaH and benzyl 45 
chloride in THF followed by a similar reaction sequence 
described for the synthesis of 4 from 13. Treatment of 
bromide 36 with 1.1 equivalent of t-butyllithium in diethyl 
ether at -78" C. followed by 1 equivalent of aldehyde 35 
gave alcohol 37 (62% yield), which was desilylated with so . I  SePh \ f i  
n-Bu,NF in THF to give alcohol 38 (63% yield). Ring s 
closure of 38 with phenylselenylphthalimide and tin tetra- 40 
chloride in dichloromethane afforded tetracyclic pyran 40 
(50% yield) with the C6a-S configuration. The phenylsele- ss 
give 40 as the major product. Acetylation of 40 with acetic 
anhydride and pyridine in dichloromethane (89% yield) 60 
followed by removal of the selenyl function with AIBN 
(2,2'-azobisisobutyronitrile) and tri-n-butyltin hydride in 
refluxing toluene gave pyran 42 (90% yield). Removal of the 
hydrogen and palladium-carbon in methanol provided diol 6s 
obtained in Scheme 4. 
"""I 
benzyl ether protecting group of 42 with 1 atmosphere of 
26, which has identical proton NMR spectrum as that 
' i =  SePh 
\ H  
41 
- 
SnC14, CH2C12 
(SO% yield) 
38 
OBn 
Ac20 
CH2C12 
pyridine 
* 
(89% yield) 
AlBN 
n-BusSnH 
toluene 
reflux 
(90% yield) 
* 
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OBn 
H2, PdIC 
MeOH . 26 
42 
EXAMPLES 
Nuclear magnetic resonance spectra were obtained at 400 
MHz for 'H and 100 MHz for I3C in deuteriochloroform, 
and reported in ppm. Infrared spectra are reported in wave- 
numbers (cm-'). Elemental analysis data were obtained 
from Desert Analytics, Tucson, Ariz. USA, and are reported 
as % C and % H. Mass spectra were taken from a Hewlett 
Packard 5890A Series 11, GC-MS. Davisil silica gel, grade 
643 (200-425 mesh), was used for the flash column chro- 
matographic separation. Tetrahydrofuran and diethyl ether 
were distilled over sodium and benzophenone before use. 
Methylene chloride was distilled over CaH, and toluene and 
benzene were distilled over LiAlH,. Chemicals and reagents 
were purchased either from Aldrich Chemical Company or 
Fisher Chemical Company, and were used without further 
purification. 
Example 1 
O Y H  
(4aS,8aS)-3,4,4a,5,6,7,8,8a-Octahydro-2,5,5,8a- 
tetramethylnaphthalene-1-carboxaldehyde 
Step 1: Preparation of (lS,3aR,SaS,9aS,9bR)-l-Hydroxy- 
dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,l-b]furan-2- 
one  (6)  and ( 1  R ,3  aR,5  a s ,  9 a s ,  9 b R) - 1 -Hydroxy-  
dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,l-b]furan-2- 
one (7) 
To a cold (-78" C.) solution of 1.02 mL (7.79 mmol) of 
diisopropylamine in 40 mL of THF under argon, was added 
6.36 mL (7.19 mmol) of n-BuLi (1.6 M in hexane). The 
solution was stirred at -78" C. for 1 h, and a solution of 1.50 
g (5.99 mmol) of (+)-sclareolide 5 in 20 mL of THF was 
added via cannula dropwise. After the solution was stirred at 
-78" C. for 1 h, the solution was added to a 5.10 g (0.012 
mol) of MoO,.pyridine.HMPA, and stirred for 30 minutes. 
The mixture was diluted with saturated aqueous Na,SO,, 
extracted three times with ethyl acetate, and the organic 
layer was washed with water, and brine, dried (Na,SO,), 
concentrated, and column chromatographed on silica gel 
using a mixture of hexane:ether (9:l) as an eluent to give 
1.045 g (65.6% yield) of compound 6 and 0.195 g (12% 
yield) of compound 9 along with 0.296 g (20% recovery) of 
30 
5. Compound 6: [~(]~~,=+97.1" (c 0.01, CHC1,); 'H NMR 
(CDC1,) 6 4.48 (d, J=12Hz, lH,  CHO, axial), 2.06 (d, 
J=12Hz, lH,  C9b-axial H), 1.95-1.06 (m, 11H), 1.38 (s,  3H, 
Me), 1.03 (s,  3H, Me), 0.88 (s,  3H, Me), 0.84 (s,  3H, Me); 
I3C NMR (CDC1,) 6 179.0 (s,  C=O), 83.5,68.7,64.2,56.4, 
42.3,39.4,39.3,36.9,33.4,33.2,23.5,21.1,20.7,18.1,15.9. 
Compound 7: [~(]~~,=-19.1" (c 0.01, CHC1,); 'H NMR 
(CDC1,) 6 4.37 (dd, J=5.6, 3.2Hz, lH, CHO, equatorial), 
i o  (m, lOH), 1.69 (s,  3H, Me), 1.21 (s,  3H, Me), 0.87 (s,  3H, 
Me), 0.85 (s,  3H, Me); I3C NMR (CDC1,) 6 177.6 (s,C=O), 
88.8,70.2,62.6,57.8,42.4,39.8,38.7,37.3,27.1,25.2,21.1, 
20.8, 18.3, 17.3. 
Step 2: Preparation of l-(lS-1,2-Dihydroxyethyl)-(lR,2R, 
is 4aS,8aS)-decahydro-2,5,5,8a-tetramethylnaphthalen-2-01 
(8s) and (lS,3aR,SaS,9aS,9bR)-Dodecahydro-3a,6,6,9a- 
tetramethylnaphtho[2,l-b]furan-1,2-diol (9s) 
The following representative method describes the reduc- 
tion of 6 and 7 to triol 8 and lactol 9. A solution of 0.90 g 
20 (3.4 mmol) of 6 in 20 mL of THF under argon, was added 
0.66 g (17.3 mmol) of LMH,, and the mixture was stirred 
for 4 h at 25" C. To it, 60 mL of water and 16 mL of 1 N HC1 
were added, and the solution was extracted with diethyl 
ether three times (50 mL each). The combined ether extracts 
2s were washed with brine, dried (MgSO,), concentrated, and 
column chromatographed on silica gel using a gradient 
mixture of hexane and ethyl acetate as an eluent to give 0.65 
g (71% yield) of triol 8s and 0.273 g (30% yield) of lactol 
9s.  Compound 8s: [ ~ ( ] " ~ ~ = - 7 . 2 "  (c 0.008, CH,OH); 'H 
30 NMR (CDC1,) 6 4.53 (m, lH,  CHO), 4.08 (dd, J=10, 8Hz, 
J=4Hz, lH), 1.70-1.01 (m, 11H), 1.43 (s,  3H, Me), 1.10 (s,  
3H, Me), 0.90 (s,  3H, Me), 0.82 (s,  3H, Me); I3C NMR 
(CDC1,) 6 82.9,75.2,71.8,68.8,48.7,42.4,38.4,36.3,34.9, 
3s 33.7, 33.2, 28.3, 23.0, 21.9, 20.0, 18.5. Compound 9 s  (as a 
mixture of 2 diastereomers at C2): 'H NMR (CDC1,) 6 5.38 
(broad s, lH), 5.33 (s,  lH), 4.35 (t, J=5Hz, lH), 2.5 (broad 
s,  lH, OH), 1.9-0.9 (m, 12H), 1.49 (s,  3H, Me), 1.19 (s,  3H, 
Me), 0.86 (s,  3H, Me), 0.84 (s,  3H, Me). 
For the 8R isomer, l-(lR-1,2-Dihydroxyethyl)-(lR,2R, 
4aS,8aS)-decahydro-2,5,5,8a-tetramethylnaphthalen-2-01 
(8R): 'H NMR (CDC1,) 6 3.87 (m, lH,  CHO), 3.68 (dd, 
3.15 (broad s, 3H, OH), 1.80-0.8 (m, 12H), 1.54 (s,  3H, 
4s Me), 0.99 (s,  3H, Me), 0.87 (s,  3H, Me), 0.81 (s,  3H, Me). 
For the 9R isomer, (lR,3aR,5aS,9aS,9bR)-Dodecahydr0-3a, 
6,6,9a-tetramethylnaphtho[2,1-b]furan-l,2-diol (9s): (as a 
mixture of 2 diastereomers at C2). 'H NMR (CDC1,) 6 5.32 
(d, J=6Hz, lH,  CHO of 1 diastereomer), 5.22 (d, J=3Hz, lH,  
SO CHO of 1 diastereomer), 4.36-4.10 (m, 2H, CHO of 2 
diastereomers), 2.80 (broad s, 4H, OH for 2 diastereomers), 
1.90-0.9 (m, 24H for 2 diastereomers), 1.34 (s,  3H, Me), 
1.16 (s,  3H, Me), 0.97 (s,  3H, Me), 0.95 (s,  3H, Me), 0.87 
(s,  6H, 2Me), 0.83 (s,  6H, 2Me); I3C NMR (CDC1,) 6 94.5, 
ss 79.2,73.1,70.8,64.3,62.9,60.6,57.1,56.9,42.5,40.8,40.4, 
39.9,37.0,36.8,33.8,33.3,25.3,25.2,24.6,21.6,21.3,20.8, 
18.4, 16.4, 16.2. 
Step 3: Preparation of (lR,2R,4aS,8aS)-Decahydro-2- 
hydroxy-2,5,5,8a-tetramethylnaphthalene-l- 
To a solution of 0.65 g (2.4 mmol) of a mixture of triol 8s 
and 8R in 25 mL of benzene under argon was added 1.3 g 
(2.9 mmol) of lead tetraacetate. After stirring at 25" C. for 
4 h, the mixture was diluted with diethyl ether, the organic 
65 layer was washed with water, and brine, dried (MgSO,), 
concentrated, and column chromatographed on silica gel 
using a gradient mixture of hexane and diethyl ether as 
5 
2.32 (d, J=3.2Hz, lH,  OH), 2.06 (d, J=12Hz, lH), 1.89-0.98 
lH,  CH,O), 3.64 (dd, J=10, ~ H z ,  lH,  CH,O), 1.95 (d, 
40 
J = l l ,  ~ H z ,  lH, CH,O), 3.42 (dd, J = l l ,  ~ H z ,  lH,  CH,O), 
60 carboxaldehyde (10) 
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eluent to give 0.516 g (90% yield) of aldehyde 10. [alZzD=+ 1984, 49, 735-6). To a solution of 0.350 g (1.10 mmol) of 
31.9" (c 0.0075, CHC1,); 'H NMR (CDC1,) 6 10.06 (d, formyloxy 11 in 20 mLof methanol was added 0.181 g (1.32 
J=3Hz, 1H, CHO), 2.93 (broad S, 1H, OH), 2.15 (d, J=3Hz, mmol) of potassium carbonate. After the solution was stirred 
1H, Cl-H), 13-0.9 (a series of m, 11H), 1.20 (S2 3H, Me), at 0" C. for 2 h, the solution was diluted with water and 
1.17 6 2  3H, Me), 0.90 6 2  3H, Me), 0.86 6 2  3H, Me); l3c s extracted three times with diethyl ether. The combined ether 
NMR (CDC1,) 6 208.3, 72.9, 71.4, 55.3, 42.9, 41.8, 39.9, extract was washed with brine, dried (MgSO,), 
37.5, 33.5, 30.5, 25.4, 21.5, 20.0, 18.3, 17.7. concentrated, and column chromatographed on silica gel 
Step 4: Preparation Of  (4aS,8aS)-3,4,4a,5,6,7,8,8a- using a gradient mixture of hexane and ether as eluent to 
a h y d r o - 2  ,5  ,5  ,8 a - t e  a m e  h y l n a p  a l e n e -  - give 0.241 (92% yield) of aldehyde 10, 
10 
carboxaldehyde (3) 
To a flask equipped with a Dean-Stark apparatus under 
argon, 10 mg (0.042 mmol) of aldehyde 10, 10 M1 of 
toluene, and 3 mg (0.017 mmol) of p-toluenesulfonic acid 
were added. After the solution was reflux for 2 h, the 
solution was cooled to 25" C., diluted with saturated aque- 
ous sodium bicarbonate, and extracted three times with ethyl 
dried (MgS04), concentrated, and column chromatographed 
on silica gel using a gradient mixture of hexane and ethyl 
acetate as eluent to give 7.2 mg (78% yield) of aldehyde 
3.14. In a larger-scale synthesis of 3, the product was 20 
distilled under reduced pressure to give colorless oil; bp. 60" 
C./3 mm Hg (to eliminate trace amount of water), and the 
distilled product was used in next step. [a]2zD=+520 (c 1, S t ep  1 :  Prepara t ion  of 3-Chloro-4-hydroxy-5-  
CHC1,); 'H NMR (CDC1,) d 10.04 (s ,  lH, CHO), 2.55 (d, methoxybenzaldehyde (12) 
J=13Hz, lH), 2.26 (dd, J=8, 4 Hz, lH), 2.03 (s,  2H, Me), zs Compound 12 was prepared according to the procedure of 
1.70-1.40 (m, 6H), 1.18 (s,  3H, Me), 1.17-0.91 (m, 2H), Hann et al. (J. Am. Chem. SOC. 1927, 49, 535-7). To a 
0.90 (s,  3H, Me), 0.86 (s,  3H, Me); I3C NMR (CDC1,) d solution of 2.50 g (16.4 mmol) of vanillin in 15 mLof glacial 
192.8 (C=O), 153.7 (C=C), 143.9 (C=C), 51.8, 41.8, acetic acid was added chlorine gas through a glass tubing 
37.8, 36.7, 36.4, 33.6, 33.5, 33.2, 21.8, 20.4, 19.1, 18.5. over 30 minutes (with a slow gas flow) at 25" C. White solid 
30 product was collected by filtration, washed with 50 mL of Example 2 hexane, and dried in vacuo to give 2.033 g of 12. The acetic 
acid filtrate was again treated with chlorine gas as above for 
30 minutes to give another 0.659 g of 12. A total of 2.691 g 
(88% yield) of 12 was obtained. The white solids were used 
35 in next step without purification. 'H NMR (CDC1,) 6 10.04 
(s, lH,  OH), 9.76 (s, lH,  CHO), 7.56 (d, J=1.6 Hz, lH,Ar), 
7.37 (d, J=1.6Hz, lH,  Ar), 3.91 (s,  3H, OMe); I3C NMR 
(CDC1,) 6 190.5 (C=O), 149.0 (s,  2C), 128.2 (s) ,  125.6 (d), 
120.1 (s) ,  109.2 (d), 56.3 (9). 
40 Step 2: Preparation of 5-Chloro-3,4-dihydroxybenzaldehyde 
To a solution 2.00 g (10.7 mmol) of benzaldehyde 12 in 
20 mL of dichloromethane under argon at 0" C. was added 
1.20 mL (11.8 mmol) of boron tribromide. The solution was 
stirred at 0" C. for 0.3 h and 25" C. for 4 h, diluted with 40 
Preparation of (lR,2R,4aS,8aS)-Decahydro-2- 
hydroxy-2,5,5,8a-tetramethylnaphthalene-l- 
carboxaldehyde 
Step 1: Preparation of (lR,2R,4aS,8aS)-Decahydro-2- 45 mL of methanol, and the solvents were removed on a rotary 
f o  r m y l o x y - 2 , 5 , 5 , 8  a -  te  t r ame  t h y l n a p  h t h a l e n e  - 1 - evaporator (the trimethylborate was removed). To it was 
carboxaldehyde (11) added 40 mLof methanol and methanol and trimethyl borate 
To a solution of 0.30 g (1.1 mmol) of lactols 9 s  and 9R were removed by evaporation on a rotary evaporator, and 
in 15 mL of benzene under argon was added 0.60 g (1.3 this process was repeated three times. The residue was 
mmol) of lead tetraacetate. After the mixture was stirred at SO diluted with dichloromethane and filtered and washed with 
25" C. for 4 h, it was diluted with diethyl ether, the organic a small amount of dichloromethane to give 1.722 g (94% 
layer was washed with water, and brine, dried (MgSO,), yield) of pure 5-chloro-3,4-dihydroxybenzaldehyde. This 
concentrated, and column chromatographed on silica gel material was used in next step without purification. 'H NMR 
using a gradient mixture of hexane and diethyl ether as (CDC1,) 6 10.43 (s,  2H, OH), 9.70 (s,  lH, CHO), 7.42 (d, 
eluent to give 0.25 g (85% yield) of aldehyde 11. [alZzD=- ss J=2.0Hz, lH,  C6-H), 7.22 (d, J=2.0Hz, lH,  C2-H); I3C 
Example 3 
Me2t-Bu-Si0 , q O S i - t - B u M e 2  
c1 
acetate. The combined extracts were washed with brine, Me2t-Bu-Si0 Br 
Preparation of 5-Bromo-6-chloro-1,2,4-tris-(t- 
butyldime thylsily1oxy)benzene 
O w H  
,'/OH 
. -  I  
\ H  (jjY 
54.4" (C 0.25, CHC1,); 'H NMR (CDC1,) 6 9.98 (d, J=4Hz, 
lH,  CHO), 7.92 (s, lH, OCHO), 2.55 (dd, J=9.6,3.2Hz, lH,  
NMR (DMSO-d,) 6 190.6 (C=O), 148.3 (s), 146.9 (s), 
128.4 (d), 124.2 (d), 120.3 (s), 112.5 (s). 
C4a-H), 2.49 (d, J=4Hz, lH,  C1-H), 1.85 (s,  3H, Me), 
1.84-0.90 (m, lOH), 1.18 (s,  3H, Me), 0.89 (s,  3H, Me), 0.83 
(s,  3H, Me); I3C NMR (CDC1,) 6 204.2 (C=O), 160.1 60 
(C=O), 85.9, 68.9, 55.1, 41.7, 40.0, 39.9, 39.1, 33.4, 22.3, 
21.6, 21.5, 20.0, 18.1, 17.2. 
Step 2: Preparation of (lR,2R,4aS,8aS)-Decahydro-2- 
h y d r o x y  - 2 , 5 , 5 , 8  a - t e t r am e t h y In a p  h t h a l e  n e - 1 - 
carboxaldehyde (10) 
5-Chloro-3,4-dihydroxybenzaldehyde was prepared 
according to the procedure of Jong et al. (J. Org. Chem. 
Step 3: Preparation of 3,4-bis(t-Butyldimethylsilyloxy)-5- 
chlorobenzaldehyde (13) 
To a solution of 1.68 g (9.70 mmol) of 5-chloro-3,4- 
dihydroxybenzaldehyde and 0.212 g (2.80 mmol) of 
4-dimethylaminopyridine (DMAP) in 20 mL of dichlo- 
romethane under argon at 0" C. were added 9.80 mL (68.0 
mmol) of distilled triethylamine and 4.40 g (59.2 mmol) of 
65 t-butyldimethylsilyl chloride. The reaction mixture was 
stirred at 0" C. for 1 h and 25" C. for 3 h, 100 mLof saturated 
aqueous NH,C1 was added, and extracted three times with 
US 6,727,277 B3 
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diethyl ether (80 mL each). The combined extracts were 
washed with 60 mL of brine, dried (MgSO,), concentrated, 
and column chromatographed on silica gel using a gradient 
mixture of hexane and diethyl ether as eluent to give 3.64 g 
(93% yield). 'H NMR (CDC1,) 6 6 9.77 (s,  lH,  CHO), 7.50 
(s,  9H, t-Bu), 0.98 (s,  9H, t-Bu), 0.26 (s,  6H, Me), 0.23 (s,  
6H, Me); I3C NMR (CDC1,) 6 189.3 (C=O), 149.5 (s) ,  
149.2 (s) ,  130.3 (s) ,  127.8 (s) ,  125.7 (d), 118.8 (d), 26.1 (q, 
3C, t-Bu), 26.0 (q, 3C, t-Bu), 18.7 (s,  2C, t-Bu), -3.4 (q, 2C, 
Me), -3.6 (q, 2C, Me). Anal. Calc for C,,H,,ClO,Si,: C, 
56.90; H, 8.29. Found: C, 56.62; H, 8.41. 
Step 4: Preparation of 3,4-bis-(t-Butyldimethylsilyloxy)-5- 
chlorophenyl Formate 
To a solution of 1.73 g (4.30 mmol) of 13 in 15 mL of 
dichloromethane under argon was added 2.03 g (6.50 mmol) 
of 55% m-chloroperbenzoic acid (MCPBA). After refluxing 
for 10 h, the solution was diluted with 30 mL of water and 
extracted three times with diethyl ether (50 mL each). The 
combined extracts were washed twice with saturated aque- 
ous NaHCO, (30 mL each), 30 mL of water, and 30 mL of 
brine, dried (MgSO,), concentrated, and column chromato- 
graphed on silica gel using hexane as eluent to give 1.24 g 
(70% yield) of 3,4-bis-(t-butyldimethylsilyloxy)-5- 
chlorophenyl formate. 'H NMR (CDC1,) 6 8.22 (s,  lH,  
9H, t-Bu), 0.96 (s,  9H, t-Bu), 0.22 (s,  6H, Me), 0.19 (s,  6H, 
Me); I3C NMR (CDC1,) 6 159.0 (s,  C=O), 148.8 (s) ,  143.0 
(s) ,  142.4 (s) ,  127.1 (s) ,  115.5 (d), 113.1 (d), 26.2 (q, 6C, 
t-Bu), 18.8 (s,  2C, t-Bu), -3.3 (q, 2C, Me), -3.6 (q, 2C, Me). 
Step 5: Preparation of 1,2,5-tris-(t-Butyldimethylsilyloxy)- 
3-chlorobenzene (14) 
To a mixture of 1.028 g (2.65 mmol) of 3,4-bis-(t- 
butyldimethylsilyloxy)-5-chlorophenol, 0.600 g (4.00 
mmol) of t-butyldimethylsilyl chloride, and 0.048 g (0.40 
mmol) of 4-dimethylaminopyridine in 10 mL of dichlo- 
romethane under argon at 25" C. was added 1.30 mL (9.26 
mmol) of triethylamine. After stirring at 25" C. for 10 h, the 
mixture was diluted with 30 mL of water and extracted three 
times with diethyl ether (50 mL each). The combined 
extracts were washed with 30 mL of brine, dried (MgS04), 
concentrated, and column chromatographed on silica gel 
using a gradient mixture of hexane and diethyl ether as 
eluent to give 1.100 g (83% yield) of 14. 'H NMR (CDC13) 
C6-H), 1.04-0.97 (broad s,  27H, t-Bu), 0.18 (s,  6H, Me), 
0.175 (s,  12H, Me); I3C NMR (CDC1,) d 149.3 (s) ,  148.6 
(s) ,  138.6 (s) ,  126.8 (s) ,  114.6 (d), 112.1 (d), 26.3 (q, t-Bu), 
25.9 (q, t-Bu), 18.9 (s) ,  8.8 (s) ,  -3.5 (q, 2C, Me), -3.4 (q, 2C, 
Me), -4.3 (q, 2C, Me). Anal. Calcd for C,,H,,ClO,Si,: C, 
57.27; H, 9.41. Found: C, 57.37; H, 9.55. 
Step 6: Preparation of 5-Bromo-6-chloro-1,2,4-tris-(t- 
butyldimethylsily1oxy)benzene (4) 
Amixture of 0.650 g (1.30 mmol) of 14 and 0.276 g (1.60 
mmol) of N-bromosuccinimide (NBS) in 10 M1 of DMF 
under argon was stirred at 25" C. for 5 days. The reaction 
mixture was diluted with 30 M1 of water, extracted three 
times with diethyl ether (50 M1 each), and the combined 
extracts were washed with 30 M1 of water, and 30 M1 of 
brine, dried (MgSO,), concentrated, and column chromato- 
graphed on silica gel using a gradient mixture of hexane and 
diethyl ether as eluent gave 0.506 g (67% yield) of bromide 
4. 'H NMR (CDC1,) 6 6.41 (s,  lH,  Ar, C3-H), 1.03 (s,  9H, 
t-Bu), 1.02 (s,  9H, t-Bu), 0.97 (s,  9H, t-Bu), 0.23 (s,  6H, Me), 
0.22 (s,  6H, Me), 0.18 (s,  6H, Me); I3C NMR (CDC1,) 6 
147.3 (s) ,  147.2 (s) ,  139.4 (s) ,  128.3 (s) ,  111.1 (d), 108.4 (s) ,  
29.9 (q, t-Bu), 26.3 (q, t-Bu), 26.2 (q), 26, 18.9 (s) ,  18.6 (s) ,  
(d, J=2.0 Hz, lH, C6-H), 7.27 (d, J=2.0 Hz, lH,  C2-H), 1.04 
CHO), 6.79(d,J=3.2H~, lH), 6.58 (d,J=3.2Hz, lH), 1.03 (s, 
d 6.49 (d, J=2.8 Hz, lH,  Ar, C4-H), 6.30 (d, J=2.8 Hz, lH,  
34 
-3.3 (q, Me), -3.4 (q, Me), -3.5 (q, Me), -4.0 (9). Anal. 
Calcd for C,,H,,BrClO,Si,: C, 49.51; H, 7.96. Found: C, 
49.78; H, 8.11. 
S 
Example 4 
1s 
5-Bromo-6-chloro-l,2,4-tris-(t- 
butyldime thylsily1oxy)benzene 
Step 1: Preparation of 3,4-bis-(t-Butyldimethylsilyloxy)-5- 
chlorophenol (16) 
20 
To a solution of 1.236 g (2.97 mmol) of 3,4-bis-(t- 
butyldimethylsilyloxy)-5-chlorophenyl formate in 10 mL of 
methanol was added 2.05 g (15.0 mmol) of potassium 
carbonate at 25" C. The solution was stirred for 30 min., 
diluted with 35 mL of water, and extracted three times with 
diethyl ether (50 mL each). The combined extracts were 
3o washed with brine, dried (MgSO,), and concentrated to give 
1.028 g (90% yield) of 3,4-bis-(t-butyldimethylsilyloxy)-5- 
chlorophenol. 'H NMR (CDC1,) d 6.45 (d, J=2.8 Hz, lH), 
0.18 (s,  6H, Me), 0.15 (s,  6H, Me); I3C NMR (CDC13) d 
3s 149.7 (s) ,  148.9 (s) ,  137.7 (s) ,  126.9 (s) ,  109.8 (d), 107.8 (d), 
26.3 (q, 3C), 26.2 (q, 3C), -3.6 (q, 2C, Me), -3.4 (q, 2C, 
Me). Anal. Calcd for C,,H,,ClO,Si,: C, 55.57; H, 8.55. 
Found: C, 55.39; H, 8.87. 
2s 
6.31 (d, J=2.8 Hz, lH), 1.00 (s, 9H, t-Bu), 0.93 (s, 9H, t-Bu), 
40 Step 2: Preparation of 2-Bromo-3-chloro-4,5-bis-(t- 
butyldimethylsi1yoxy)phenol (17) 
Asolution of 0.050 g (0.12 mmol) of 16 and 0.023 g (0.12 
mmol) of NBS in 2 mL of DMF under argon was stirred at 
4s 25" C. for 1 day. The reaction mixture was diluted with 30 
mL of water, extracted three times with diethyl ether (40 mL 
each), and the combined extracts were washed with brine 
(30 mL), dried (MgSO,), and concentrated to give 0.042 g 
(70% yield). This material was used in next step without 
50 purification. 'H NMR (CDC1,) 6 6.53 (s,  lH,  Ar, C6-H), 
1.03 (s,  9H, t-Bu), 0.96 (s,  9H, t-Bu), 0.22 (s,  6H, Me), 0.17 
(s,  6H, Me); I3C NMR (CDC1,) 6 148.3 (s) ,  147.4 (s) ,  138.8 
(s) ,  127.0 (s) ,  106.9 (d), 102.9 (s) ,  26.2 (q, t-Bu), 18.8 (s) ,  
-3.3 (q, Me), -3.5 (q, Me). 
Step 3: Preparation of 5-Bromo-6-chloro-l,2,4-tris-(t- 
but yldime thylsily1oxy)benzene 
5s 
To a mixture of 0.042 g (0.090 mmol) of 17,0.016 g (0.11 
60 mmol) of t-butyldimethylsilyl chloride, and 0.003 g (0.010 
mmol) of DMAP in 2 mL of dichloromethane under argon 
at 25" C. was added 0.05 mL (0.260 mmol) of triethylamine. 
The reaction mixture was stirred for 3 h, diluted with 30 mL 
of water, and extracted three times with diethyl ether (30 mL 
6s each). The combined ether extracts were with 30 mL of 
brine, dried (MgSO,), and concentrated to give 0.051 g 
(99% yield) of 4. 
US 6,727,277 B1 
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Example 5 of 18 and 0.200 g (9.1% yield) of 19. Compound 18: 
[a]22D=+560 (c 0.033, CHC1,); 'H NMR (CDC1,) 6 6.43 (s,  
(d, J=12 Hz, lH), 1.90-1.00 (a series of m, 9H), 1.37 (s,  3H, 
s Me), t-BuSi), 1.16 0.92 (s,  (s ,  3H, 3H, Me), Me), 1.03 0.87 (s,  (s ,  9H, 3H, t-BuSi), Me 0.95 21 (s,  3H, 9
MeSi), 0.20 (s,  3H, MeSi), 0.17 (s,  9H, MeSi), 0.16 (s,  3H, 
MeSi); I3C NMR (CDC1,) 6 151.3, 147.3, 146.1, 138.1, 
123.6, 115.7, 111.7, 107.9,78.0, 52.4,41.8,41.7,39.5, 38.2, 
i o  33.8,33.6,26.4 (3C, t-Bu), 26.3 (3C, t-Bu), 26.1,23.7,21.9, 
19.5, 19.1, 18.9, -3.2, -3.46, -3.49, -3.6. Compound 19: 
[a]22D=+500 (c 0.018, CHC1,); 'H NMR (CDC1,) 6 6.39 (s,  
lH,  C8-H), 6.31 (s,  lH,  C12-H), 2.20-0.90 (m, 11H), 1.31 
(s,  3H, Me), 1.23 (s,  3H. Me), 1.03 (s,  9H, t-Bu), 0.96 (s,  9H, 
A solution of 0.100 g (0.20 mmol) of 14 and 0.0354 g t-Bu), 0.95 3H, Me), o.86 3H, Me), o.21 3H, MeSi), 
(0.20 mmol) of NBS in 2 mL of DMF under argon was o.20 3H, Me), 0.18 3H, Me), 0.15 3H, Me); 
stirred at 50" C. for 2 day. The solution was diluted with 30 NMR (CDC13) 151.9, 147.5, 146.0, 138.0, 123.8, 116.5, 
mL of water, extracted three times with diethyl ether (30 mL 111.9, 108.0, 78.0, 52.2, 44.1,42.3, 39.4,39.1, 34.0, 33.0, 
each), and the combined extracts were washed with brine, 31.1, 26.4 (3c, t-Bu), 26.3 (3c, t-Bu), 26.1, 25.6, 25.1, 23.7, 
dried (MgSO,), concentrated, and column chromatographed 20 21.4, 19.2, 18.9, 18.8, 17.6, -3.3, -3.4, -3.5, -3.6. Anal. 
on silica gel using a mixture of hexane and diethyl ether Calcd for C33HssC103Siz: c, 67.02; H, 9.37. Found: c, 
(1OO:l) as eluent to give 31.4 mg (27% yield) of 4 and 62.9 67.11; H, 9.16. 
lH,  C8-H), 6.28 (s, lH, C12-H), 2.18 (d, J=12 Hz, lH), 2.02 
Me2t-Bu-SiO@OSi-t-BuMe2 
Me2t-Bu-Si0 
c1 
2-Bromo-5-chloro-1,3,4-tris-(t- 
butyldimethylsily1oxy)benzene 
mg (54% yield) of 15, Compound 15: 'H NMR (CDC1,) 6 2D NOESY spectra were obtained and in compound 18, 
6.54 (s,  1H, A, C6-H), 1.03 (s,  18H, t-Bu), 0.97 (s,  9H, C6a and C12b have connectivity, 
t-Bu), 0.23 (s,  12H, Me), 0.17 (s,  6H, Me). zs however, in compound 19, C6a methyl and C12b methyl 
have no NOE connectivity. 
Step 2: Preparation of(4aS,6aR,12bS)-2H-ll-Chloro-1,3,4, 
4a,5,6,6a,12b-octahydro-4,4,6a,12b-tetramethyl-benzo[a] 
To a solution of 0.160 g (0.270 mmol) of 18 in 3 mL of 
THF under argon at 25" C. was added 0.58 mL (0.600 mmol) 
of tetra-n-butylammonium fluoride (1.0 M in THF). After 
stirring at 25" C. for 5 min., 0.30 mL of acetic acid was 
added, the resulting solution was concentrated on a rotary 
35 evaporator, and column chromatographed on silica gel using 
a gradient mixture of hexane and ethyl acetate as eluent to 
give 0.080 g (82% yield) of 1. [ ~ ( ] ~ ~ ~ = + 0 . 1 1 "  (c 0.018, 
CH,Cl,); 'H NMR (CDC1,) 6 6.42-6.20 (broad s, 3H, C8H, 
C12H, and OH), 5.8 (broad s,  lH, OH), 2.18 (d, J=12 Hz, 
40 lH), 2.01 (d, J=12 Hz, lH), 1.86-0.90 (a series of m, 9H), 
1.42 (s,  3H, Me), 1.15 (s,  3H, Me), 0.92 (s,  3H, Me), 0.87 
(s,  3H,Me); 13CNMR(CDC13) 6 151.3,147.3,146.1,138.1, 
Step 1: Preparation of (4aS,6aR,12bS)-2H-9,10-bis-(t- 123.6,115.7,111.7,107.9,78.0,42.3,41.8,38.2,34.0,33.9, 
Butyldimethylsilyloxy)-ll-chloro-1,3,4,4a,5,6,6a,l2b- 33.5, 33.0, 21.9, 21.4, 20.9, 19.5, 19.1. 
octahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene (18) 45 
and (4aS,6aS,12bS)-2H-9,l0-bis-(t-Butyldimethylsilyloxy)- 
ll-chloro-1,3,4,4a,5,6,6a,l2b-octahydro-4,4,6a,l2b- 
tetramethyl-benzo[a]xanthene (19) 
In a dried flask, 2.600 g (4.50 mmol) of bromide 4 was 
placed, it was dried by adding 1 mL of freshly distilled SO 
toluene (distilled over sodium) followed by evaporation 
under vacuum, this addition-evaporation of toluene process 
was repeated, and maintained under argon. To it, 25 mL 
diethyl ether (freshly distilled over sodium-benzophenone) 
was added, cooled to -78" C., and 2.7 mL (4.50 mmol) of 55 
t-BuLi (1.7 M in pentane) was added via syringe. After 
stirring at -78" C. for 0.5 h, a solution of 0.820 g (3.70 
mmol) of aldehyde 3 (distilled under reduced pressure) in 10 
resulting solution was stirred at -78" C. for 10 min., 25" C. 60 
for 1 h (the reaction was monitored by TLC). The reaction 
solution was diluted with 10 mL of saturated aqueous 
NH,C1, extracted three times with diethyl ether, and the 
combined extracts were washed with water, and brine, dried 
(MgSO,), concentrated, and column chromatographed on 65 
silica gel using a gradient mixture of hexane and toluene and 
then hexane and ether as eluents to give 0.980 g (45% yield) 
Example 6 
(1) xanthene-9,lO-diol (1) 
30 
OH 
+@ 
. =  $ E  
s 
Example 7 
8
&OH 
: I . -  
mL of diethyl ether (-78" C.) was added via cannula, and the $ H  
(4aS,6aS,12bS)-2H-ll-Chloro-1,3,4,4a,5,6,6a,l2b- 
octahydro-4,4,6a,12b-tetramethyl-benzo[ alxanthene- 
9,lO-diol 
To a solution of 60 mg (0.10 mmol) of 19 in 2 mL of THF 
under argon at 25" C. was added 0.22 mL (0.22 mmol) of 
US 6,727,277 B1 
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tetra-n-butylammonium fluoride (1.0 M in THF). After 146.5, 137.4, 126.8, 114.4, 108.2, 76.8, 56.4, 52.2, 42.1, 
stirring at 25" C. for 10 min., 0.10 mL of acetic acid was 41.1,39.4,37.1,33.7,33.4,26.4 (3C, t-Bu), 26.3 (3C, t-Bu), 
added, the solution was concentrated on a rotary evaporator, 25.2, 24.1, 21.8, 20.7, 20.0, 18.9, 18.7, 15.0 -3.2 (MeSi), 
and the residue was column chromatographed on silica gel -3.4, -3.5 (2c). Anal. Calcd for C,,H,,C10,Si2: c ,  66.79; 
using a gradient mixture of hexane and ethyl acetate as 5 H, 9.68. Found: C, 67.15; H, 9.45. 
eluent to give 30 mg (81.4% yield) of 2, [a]22D=+1,1~ (. Step 2: Preparation of (4aS,6aR,12aR,12bS)-2H-ll-Chloro- 
0.014, CHC1,); 'H NMR (CDC1,) 6 6.38 (s, i ~ ,  c ~ H ) ,  6.31 1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,l2b- 
(s,  lH, C12H), 5.36 (broad s,  lH, OH), 5.03 (broad s, lH,  tetrameth~i-benzo[a1xanthene-9~i0-dioi (22) 
OH), 2.20-1.05 (a series of m, 11H), 1.44 (s,  3H, Me), 1.23 mL Of 
(CDC1,) 6 151.3, 148.5, 146.1, 133.6, 123.6, 116.5, 110.6, Of tetra-n-butylammonium fluoride ( l  in THF). The 
21.2, 20.5, 18.9, 17.2. added, the resulting red solution was concentrated to 
dryness, and column chromatographed on silica gel using a 
15 gradient mixture of hexane and ethyl acetate to give 20 mg 
(83% yield) of diol 22. 'H NMR (CDC1,) 6 6.35 (s,  lH,  
C8H), 5.33 (broad s,  lH,  OH), 5.06 (broad s,  lH, OH), 2.61 
(d, J=17 Hz, lH,  C12H), 2.34 (m, lH, C12H), 2.02 (m, lH), 
1.80-0.90 (a series of m, l lH),  1.14 (s,  3H, Me), 0.91 (s,  6H, 
2o Me), 0.85 (s,  3H, Me). When the proton NMR spectrum was 
measured in benzene-d6 solvent, all methyl groups are 
separated, 6 0.99 (s,  3H, Me), 0.77 (s,  3H, Me), 0.71 (s,  3H, 
Me), 0.61 (s,  3H, Me). I3C NMR (C,D,) 6 (the aromatic 
carbons are not well defined and are not described here) 
25 76.6,55.9,51.9,41.9,41.0,39.0,36.8,33.4,33.1,30.0,21.6, 
19.8, 19.1, 18.7, 14.7. 
Step 3: (4aS,6aR,l2aR,12bS)-2H-ll-Chloro-l,3,4,4a,5,6, 
(24) 6a,9,10,12,12a,12b-dodecahydro-4,4,6a,12b-tetramethyl- 
benzo[a]xanthene-9,1O-dione (23) and (4aS,6aR,12aR, 
0 3o 12bS)-2H-ll-Chloro-l,3,4,4a,5,6,6a,9,10,12b-decahydro-4, 
4,6a,12b-tetramethyl-benzo[a]xanthene-9,l0-dione (24) 
To a solution of 10 mg (0.027 mmol) of diol 22 in 1 mL 
of dichloromethane under argon at 25" C. was added 3 mg 
of pyridinium dichromate (PDC). After stirring for 2 h, the 
,\\@ 35 mixture  w a s  d i lu ted  wi th  a sma l l  amount  of 
dichloromethane, filtered through Celite, and concentrated 
to dryness to give 9.0 mg of a mixture of 23 and 24 in a ratio 
of 6:l  (obtained from NMR spectrum). 'H NMR (CDC1,) 6 
6.74 (s,  lH, C12H of 24), 5.95 (s,  lH, C8H of 24), 5.80 (s,  
4o lH,  C8H of 23), 2.84 (dd, J=20,5 Hz, lH,  C12H of 23),2.50 
(dd, J=20,13 Hz, C12H of 23), 2.11 (dt, J=13,3 Hz, lH, 23), 
2.22-0.90 (a series of m, 11H of 23 and 11H of 24), 1.33 (s,  
3H, Me of 23), 0.93 (s,  3H, Me of 23), 0.92 (s,  3H, Me of 
23), 0.85 (s,  3H, Me of 23). 
Example 9 
To a Of 39 mg (o.066 mmol) Of 21 in 
(s,  3H, Me), 0.96 (s ,  3H, Me), 0.87 (s,  3H, Me); I3C NMR 10 THF under argon at 250 '. was added o.20 mL (o.20 mmol) 
103.0, 78.0, 43.8, 42.0, 39.1, 33.8, 32.7, 30.8, 30.3, 25.0, drop Of acetic acid was was stirred for 30 
Example 8 
(23) 
0 
I =  . -  
$ H  8 
(4aS,6aR,12aR,12bS)-2H-ll-Chloro-l,3,4,4a,5,6,6a, 
9,10,12,12a,12b-dodecahydro-4,4,6a,12b- 
tetramethyl-benzo[a]xanthene-9,1O-dione (23) and 
(4aS,6aR,12aR,12bS)-2H-ll-Chloro-l,3,4,4a,5,6,6a, 45
9,10,12b-decahydro-4,4,6a,l2b-tetramethyl-benzo[ a] 
xanthene-9,lO-dione (24) 
Step 1: Preparation of (4aS,6aR,12aR,12bS)-2H-9,lO-bis-(t- 
Butyldimethylsilyloxy)-ll-chloro-1,3,4,4a,5,6,6a,l2,12a, 
12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene SO 
A mixture of 0.180 g (0.300 mmol) of compound 18 and 
0.400 g of 10% palladiumicarbon in 7 mL of distilled 
the use of a hydrogen balloon), and the mixture was stirred ss 
at 25" C. for 2 h. The reaction mixture was filtered through 
,II: (21) 
ethanol was charged with 1 atmosphere of hydrogen gas (by 
a short Celite column, washed the column with ethanol, and 
I O  
: : 
$ H  the combined filtrate was concentrated, and column chro- Q 
matographed on silica gel using a gradient mixture of 
hexane and toluene as eluent to give 0.180 g (99% yield) of 60 
21. [~(]~~,=+35.6" (c 0.008, CHCl,); 'H NMR (CDCl,) 6 
6.23 (s,  lH,  C8H), 2.64 (dd, J=17, 5 Hz, IH, C12H), 2.33 
(dd, J=17, 12 Hz, lH,  C12H), 2.02 (dt, J=12, 3 Hz, lH), 
1.80-1.15 (a series of m, 11H), 1.12 (s,  3H, Me), 1.03 (s,  9H, 
t-Bu), 0.95 (s,  9H, t-Bu), 0.90 (s,  6H, Me), 0.85 (s,  3H, Me), 65 (25) 
0.194 (s,  3H, MeSi), 0.191 (s,  3H, MeSi), 0.17 (s,  3H, 
MeSi), 0.15 (s,  3H, MeSi); I3C NMR (CDC1,) 6 147.4, 
(+)-Chloropuupehenone 
Step 1: Preparation of (4aS,6aS,12aR,12bS)-2H-9,1O-bis-(t- 
Butyldimethylsilyloxy)-ll-chloro-1,3,4,4a,5,6,6a,l2,12a, 
12b-decahydro-4,4,6a,l2b-tetramethyl-benzo[a]xanthene 
A mixture of 0.060 g (0.10 mmol) of compound 19 and 
0.080 g of 10% palladiumicarbon in 2 mL of distilled 
US 6,727,277 B3 
39 
ethanol was charged with 1 atmosphere of hydrogen gas (by 
the use of a hydrogen balloon), and the mixture was stirred 
at 25" C. for 2 h. The reaction mixture was filtered through 
Celite, washed with dichloromethane, and the combined 
filtrate was concentrated, and column chromatographed on 
silica gel using a gradient mixture of hexane and toluene as 
eluent to give 0.54 g (90% yield) of compound 25. [alZzD=- 
35" (c 0.007, CHC1,); 'H NMR (CDC1,) 6 6.21 (s,  lH,  
C8H), 2.75 (d, J=18 Hz, lH,  C12H), 2.64 (dd, J=18, 8 Hz, 
lH,  C12H), 2.10 (d, J = l l  Hz, lH), 1.85 (d, J=12 Hz, lH), 
1.62-1.10 (a series of m, lOH), 1.11 (s,  3H, Me), 1.03 (s,  9H, 
t-Bu), 0.95 (s,  9H, t-Bu), 0.89 (s,  3H, Me), 0.81 (s,  3H, Me), 
0.64 (s,  3H, Me), 0.20 (s,  3H, MeSi), 0.18 (s,  3H, MeSi), 
0.16 (s,  3H, MeSi), 0.157 (s,  3H, MeSi); 13C NMR (CDC1,) 
6 148.9, 146.3, 137.3, 126.0, 114.6, 108.4,75.4, 55.5, 49.7, 
42.1,40.7,40.3,38.6,33.9,33.5,27.1,26.4 (3C, t-Bu), 26.3 
(3C, t-Bu), 22.1, 21.9, 18.9, 18.7, 18.5, 14.1, -3.3 (2C, 
MeSi), -3.5, -3.6. Anal. Calcd for C,,H,,ClO,Si,: C, 
66.79; H, 9.68. Found: C, 66.92; H, 9.78. 
Step 2: Preparation of (4aS,6aS,12aR,12bS)-2H-ll-Chloro- 
1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b- 
tetramethyl-benzo[a]xanthene-9,1O-diol (26) 
To a solution of 50 mg (0.084 mmol) of 25 in 2 mL of 
THF under argon at 25" C. was added 0.25 mL (0.25 mmol) 
of tetra-n-butylammonium fluoride (1 M in THF). The 
solution was stirred for 15 min., 1 drop of acetic acid was 
added, the resulting red solution was concentrated to 
dryness, and column chromatographed on silica gel using a 
gradient mixture of hexane and ethyl acetate to give 10 mg 
(50% yield) of diol 26. [a]22D=+0.220 (c 0.036, CHC1,); 'H 
NMR (CDC1,) 6 6.33 (s,  lH,  C8H), 5.20 (broad s,  2H, OH), 
C12H), 1.84 (d, J=13 Hz, lH), 1.60-0.90 (a series of m, 
11H), 1.12 (s,  3H, Me), 0.89 (s,  3H, Me), 0.81 (s,  3H, Me), 
0.67 (s,  3H, Me); 13C NMR (CDC1,) 6 149.1, 143.1, 133.3, 
119.1, 112.4, 103.3, 75.7, 68.2, 55.4, 49.4, 42.1, 40.6, 40.3, 
38.5, 33.9, 33.4, 27.1, 22.1, 18.7, 18.4, 14.3. 
Step 3: Preparation of (+)-Chloropuupehenone (27) 
To a solution of 6.0 mg (0.016 mmol) of 26 in 1 mL of 
dichloromethane under argon at 25" C. was added 12 mg 
(0.032 mmol) of PDC. After stirring for 15 min., the solution 
was filtered through Celite, rinsed with diethyl ether, con- 
centrated and column chromatographed on silica gel using a 
gradient mixture of hexane and diethyl ether as eluent to 
give 3.0 mg (50% yield) of chloropuupehenone (27). MS 
(CI) m/z 363, 362 (M+1 and M+), 211, 173, 84. 'H NMR 
2.18 (d, J=7 Hz, lH, C12aH), 1.80-0.80 (a series of m, 11H), 
1.24 (s,  3H, Me), 0.93 (s,  3H, Me), 0.86 (s,  3H, Me), 0.82 
(s,  3H, Me); 13C NMR (CDC1,) 6 180.0 (C=O), 162.7, 
144.4, 141.2, 127.7, 125.7, 105.2, 79.3, 54.9, 54.0, 41.8, 
41.2, 40.3, 39.2, 33.9, 33.6, 28.2, 22.2, 18.6, 18.3, 15.4. 
'H and 13C NMR spectral data are similar to those 
reported (Hanann, M. T.; Scheuer, P. J., J. Org. Chem., 1993, 
58, 6565-6569). 
3-Chloro-4,5-dibenzyloxybenzaldehyde: Anal. Calcd for 
C,,H1,C10,: C, 71.49; H, 4.86. Found: C, 71.24; H, 5.00. 
3-Chloro-4,5-dibenzyloxyphenal: Anal. Calcd. For 
C20H17C103: C, 70.49; H, 5.03. Found: C, 70.13; H, 5.11. 
4-Bromo-3-chloro-1,2-dibenzyloxy-5-(t- 
butyldimethylsi1yoxy)benzene (36): Anal. Calcd for 
C,,H,,BrClO,Si: C, 58.48; H, 5.66. Found: C, 58.81; H, 
5.74. 
Example 10 
Lymphatic Absorption of Cholesterol 
Ten male Sprague-Dawley rats (Harlan Sprague Dawley, 
Inc., Indianapolis, Ind.) weighing 274.3273 grams were 
2.72 (d, J=17 Hz, lH,  C12H), 2.64 (dd, J=17, 7 Hz, lH,  
(CDC1,) 6 7.14 (d, J=7 Hz, lH,  C12H), 5.84 (s, lH,  C8H), 
40 
housed individually in plastic cages in an environmentally 
controlled room of illumination (12: 12-h lightidark cycle 
with the dark period from 0330 to 1530), humidity 
(60-70%), and temperature (22-25" C.) throughout the 
5 study. Rats had free access to deionized water and a nutri- 
tionally adequate diet (Table 1) containing soybean oil as the 
fat source and egg white as the protein source. The diet was 
formulated according to AIN-93G recommendations (In: 
Trace Elements in Laboratory Rodents (Watson, R. R., ed.), 
pp. 3-37. CRC Press, Boca Raton, Fla.). Animals were cared 
for in an animal care facility accredited by the American 
Association for the Accreditation of Laboratory Animal 
Care. Rats were maintained in accordance with the policies 
and guidelines for animal care and use procedures of the 
Kansas State University Institutional Animal Care and Use 
Committee. 
10 
TABLE 1 
Diet composition' 
Ingredient Amount ( g k g )  
20 
Egg white 
Cornstarch 
Dextrinized cornstarch 
25 Dextrose 
Cellulose 
Soybean oil' 
Mineral mix 
Vitamin mix 
Biotin (1 mgig biotin sucrose 
Choline bitartrate 
mix) 
200.0 
396.5 
132.0 
100.0 
50.0 
70.0 
35.0 
10.0 
4.0 
2.5 
'Formulated and supplied from Dyets, Bethlehem, PA, according to the 
recommendations of the AIN.l',18 
'Contained 0.02% tert-butylhydroquinone. 
At 6 wk, rats were starved overnight for 17 h but allowed 
35 water ad libitum prior to the surgical placement of a lymph 
cannula and duodenal infusion catheter. The mesenteric 
lymph duct was cannulated as described in Koo et al., J. 
Nutr. 131: 717-722 (2001). Briefly, while rats were under 
anesthesia (2.0% halothane in 2.0 L O,/min delivered via a 
40 halothane vaporizer), a midline abdominal incision was 
made. The superior mesenteric lymph duct was cannulated 
with polyethylene tubing (SV.3 1 tubing, i.d. 0.50 mm, 0.d. 
0.80 mm; Dural Plastics, Auburn, Australia). The cannula 
was fixed in place with ethyl cyanoacrylate glue (Elmer's 
45 Products, Columbus, Ohio) and externalized through the 
right flank. An indwelling infusion catheter (SilasticB labo- 
ratory tubing, i.d. 1.0 mm, 0.d. 2.2 mm; Dow Coming, 
Midland, Mich.) was introduced via the gastric fundus into 
the upper duodenum and secured in place with a purse-string 
SO suture (4-0 Silk, Ethicon, Somerville, N.J.) around the 
fundic incision. The infusion catheter was exteriorized 
alongside the lymph cannula. After the abdominal incision 
was closed, the rats were placed in restraining cages and 
housed in a recovery chamber at 30" C. for postoperative 
55 recovery for 22-24 h. During the recovery period, rats were 
infused continuously with glucose in phosphate buffered 
saline (PBS) (in mmol/L: 277 glucose, 6.75 Na,HPO,, 16.5 
NaH,PO,, 115 NaC1, and 5 KC1; pH 6.7) v infusion catheter 
at 3.0 mL/h by a syringe pump (Harvard Apparatus, Model 
60 935, South Natick, Mass.) to ensure adequate hydration and 
nutritional status of the animals. 
After postoperative recovery, each rat was infused with a 
lipid emulsion at 3 mL/h for 8 h via the duodenal catheter in 
subdued light. The lipid emulsion consisted of 451.8 pmol 
65 triolein (95%, Sigma Chemical, St. Louis, Mo.), 33.3 kBq 
[4-14C]-cholesterol (14C-CH; specific activity, 1.85 GBqi 
mmol, American Radiolabeled Chemicals, St. Louis, Mo.), 
Fklerton, dali'f.). The total 14C-radioactivity appearing in 
hourly lymph volume (the hourly rates of I4C-CH 
absorption) was expressed as a percentage of the total 
radioactivity infused (% dose). All samples were ice chilled 
and handled in subdued light. 
Fatty Acid Analysis 
Total lipids were extracted from each lymph sample with 
a chloroformimethanol mixture. Lipid extracts were then 
hydrolyzed with methanolic NaOH, and fatty acids were 
saponified and methylated simultaneously with BF,- 
methanol. Fatty acid methyl esters (FAME) were analyzed 
by capillary gas chromatography (Hewlett-Packard, Model 
6890, Palo Alto, Calif.) using a HP-INNOWax cross-linked 
polyethylene glycol phase capillary column (15 m, i.d. 0.53 
mm; Resteck Corp., Bellefonte, Pa.). 
Statistical analysis 
All statistical analyses were performed using PC SAS 
(SAS Institute, Cary, N.C.). Repeated measures ANOVAand 
the least significance difference that were used to compare 
group means. The level of significance was determined at 
Pe0.05. 
Results 
Table 2 shows the lymphatic absorption of I4C- 
cholesterol and triolein, as well as lymph flow in rats infused 
for eight hours with lipid emulsion only (control) or con- 
taining compound 1. The lymph volume was not signifi- 
cantly different between the two treatments. However, total 
cholesterol absorption was significantly less in rats infused 
with compound 1, compared to control rats. In addition, 
absorption of triolein was significantly less in rats infused 
with compound 1 compared to control rats. Table 3 and FIG. 
1 show the percent dose of 14C-cholesterol absorbed at 
hourly intervals. FIG. 2 shows the amount of oleic acid 
absorbed in the lymph at hourly intervals. 
20 
25 
30 
3s  
40 
4s  
so 
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20.7 pmol cholesterol, 3.1 pmol a-tocopherol (all-rac-dl-a- 
tocopherol, 97%, Aldrich Chemical, Milwaukee, Wis.) as an 
antioxidant, and 396.0 pmol sodium taurocholate (Sigma 
Chemical, St. Louis, Mo.) in 24 mL of PBS buffer, pH 6.5. 
For half of the rats, the lipid emulsion contained 114.9 pmol s 
compound 1 (41.9 mg). Lipid emulsion was prepared under 
a gentle N, stream and subdued light for 55 min using a 
microprocessor-controlled ultrasonicator equipped with a 
microtip (XL-2020 Ultrasonic Liquid Processor, Misonix, 
Farmingdale, N.Y.). 10 TABLE 3 
During the duodenal infusion of lipid emulsion, lymph 
centrifuge tubes containing 4 mg Na,-EDTA and 30 pg 
Thus, compound 1 is a more potent inhibitor than green tea 
catechins, since an inhibitory effect was observed with only 
41.9 mg of compound 1. Rats exhibited no gross motor or 
behavioral abnormalities. 
Rats were sacrificed at the day end of the infusion, and the 
intestine and other organs were dissected and visually exam- 
ined. No abnormalities were found in any of the organs of 
either control or treated rats. 
samples were collected hourly in preweighed ice-chilled Control Compound 1 
n-propyl gallate (Sigma Chemical, St. Louis, Mo.) as anti- 
Time % dose 
l h  0.12 ? 0.04 
2 h  1.22 ? 0.25* 
3 h  5.31 ? 0.74 2.70 ? 0.42* 
4 h  10.16 ? 1.31 4.18 ? 0.92* 
Scientific, Fair Lawn, N.J.) and counted by scintillation 5 h  15.66 ? 1.75 5.68 ? 1.37* 
suectrometrv (Beckman LS-6500; Beckman Instruments, 6 h  22.14 ? 1.81 7.32 ? 1.78* 
7 h  29.79 ? 1.65 9.13 ? 2.41* 
8 h  37.69 ? 1.78 10.95 ? 3.29* 
0.16 ? 0.07 
1.84 ? 0.37 oxidants. A portion of each lymph sample (100 pL) was 15 
mixed with scintillation liquid (ScintiVerse; Fisher 
'Values are means ? SD and cumulative at hourly intervals, n = 5. *Sig- 
nificantly different from control rats (P < 0.05). 
Example 11 
The inhibitory effect of compound 1 on the activity of 
cholesterol ester transfer protein (CETP) was measured, 
using a crude CETP preparation derived from hamster 
plasma. The results suggested that when the dose of com- 
pound 1 exceeded 250 pM, there was an increase in HDL 
total cholesterol, HDL free cholesterol, and HDL cholesterol 
ester. These increased HDL levels suggest that compound 1 
is an inhibitor of CETP activity in vitro. 
The effect of compound 24 on inhibition of CETP was 
tested using a purified CETP preparation. CETP was purified 
and assayed according to procedures described in Tomada, 
H.; Tabata, N.; Shinose, M.; Takahashi Y.; Woodruff, H. B.; 
Omura, S. J. Antibiotics, 52: 1101-1107 (1999). As shown 
in FIG. 3, there was 50% inhibition (IC50) of CETP activity 
at 31 pM of compound 24. In comparison, Ferroverdin A, a 
known CETP inhibitor, resulted in an IC50 of about 22 pM 
(FIG. 4). The data for compound 24 suggest that compound 
24 can inhibit CETP activity in vitro. 
A number of embodiments of the invention have been 
described. Nevertheless, it will be understood that various 
modifications may be made without departing from the spirit 
and scope of the invention. Accordingly, other embodiments 
are within the scope of the following claims. 
What is claimed is: 
1. A compound of Formula I: 
TABLE 2 
55 
Lymph lipid Control' Compound 1' 
Lymph volume, mLi8 h 18.30 ? 2.43 16.59 ? 4.20 
1 4 C 4 H ,  % dosei8 h 37.69 ? 1.78 10.95 ? 3.29* 
Oleic acid, pmoli8 h 598 ? 93 253 ? 79* 
'Means ? SD, n = 5. *Significantly different from control rats (P < 0.05). 6o 
After 8 hours of treatment, the control rats (without drug) 
had a percent cholesterol absorption of 37.69%, while the y $ H  
R4 R5 treated rats (treated with compound 1) had a percent cho- 
lesterol absorption of 10.95%. Under similar test conditions, 65 
rats infused with 120.5 mg of green tea catechins per rat per wherein R, is independently hydrido, halo, alkyl, alkenyl, 
8 hours had a percent cholesterol absorption of about 10%. alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
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alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino ,  cyano,  n i t ro ,  su l fona te ,  a lkyls i ly l ,  
phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, 
arylsulfinyl, or alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, 
or phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, 
arylsulfinyl, or alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, 
phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, 
arylsulfinyl, or alkylsilyloxy; 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
and 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
2. The compound of claim 1, R, is halo, R, and R, are 
3. The compound of claim 2, wherein R, is chloro and R, 
4. The compound of claim 1, wherein R, is halo, R, and 
5. The compound of claim 4, wherein R, is chloro, R, and 
or a pharmaceutically-acceptable salt thereof. 
hydroxy, and R, and R, are alkyl. 
and R, are methyl. 
R, are alkylsilyloxy, and R, and R, are alkyl. 
R, are OSi-t-BuMe,, and R, and R, are methyl. 
5 
10 
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6. The compound of claim 1, wherein said compound has 
Formula (24): 
0 
II 
15 
7. A compound of Formula 11: 
R2 
20 
2s 
wherein R, is independently hydrido, halo, alkyl, alkenyl, 
35 alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
40 carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
45 aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, 
alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or 
alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
55 heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
60 N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
65 cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
50 
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arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
R, is independently hydrido, alkyl, or hydroxyalkyl; or 
a pharmaceutically-acceptable salt thereof, wherein 
when R, is chloro, R, and R, are not hydroxy and R, 
and R, are methyl. 
8. The compound of claim 7, wherein R, is halo, R, and 
9. The compound of claim 7, wherein R, is halo, R, and 
10. The compound of claim 9, wherein R, is chloro, R, 
11. A compound of Formula 111: 
R, are hydroxy, and R, and R, are alkyl. 
R, are alkylsilyloxy; and R, and R, are alkyl. 
and R, are OS-t-BuMe,, and R, and R, are methyl. 
wherein R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, 
alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or 
alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
S 
10 
1s 
20 
2s 
30 
3s 
40 
4s 
so 
5s 
60 
65 
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alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
and 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
or a pharmaceutically-acceptable salt thereof. 
12. The compound of claim 11, wherein R, is halo, R, and 
R, are selected from hydroxy and alkylsilyloxy, and R, and 
R, are alkyl. 
13. The compound of claim 11, wherein R, is chloro, R, 
and R, are hydroxy, and R, and R, are methyl. 
14. The compound of claim 11, wherein R, is halo, R, and 
R, are alkylsilyloxy, and R, and R, are methyl. 
15. The compound of claim 14, wherein R, is chloro, R, 
and R, are OS-t-BuMe,, and R, and R, are methyl. 
16. The compound of claim 11, wherein said compound 
has Formula (23): 
US 6,727,277 B3 
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17. A compound of Formula IV 
(IV) 
wherein R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, 
alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or 
alkylsilyloxy; 
wherein R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, 
alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or 
alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
48 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
R, is independently hydrido, alkyl, or hydroxyalkyl; 
R, is independently hydrido, hydroxy, or acyloxy; and 
R, is independently alkyl, or arylselenylalkyl; 
5 or a pharmaceutically-acceptable salt thereof. 
18. The compound of claim 17, wherein R, is halo; R, and 
R, are selected from hydroxy, alkylsilyloxy, or aralkyloxy; 
R, and R, are alkyl; R, is selected from hydrido, hydroxy, 
or acyloxy; and R, is selected from alkyl or arylselenylalkyl. 
19. The compound of claim 18, wherein R, is chloro; R, 
and R, are OSi-t-BuMe,; R, and R, are methyl; R, is 
hydrido; and R, is methyl. 
20. The compound of claim 18, wherein R, is chloro; R, 
and R, are hydroxy; R, and R, are methyl; R, is hydrido; 
21. The compound of claim 18, wherein R, is chloro; R, 
and R, are arylalkyloxy; R, and R, are methyl; R, is 
hydroxy; and R, is arylselenylalkyl. 
22. The compound of claim 18, wherein R, is chloro; R, 
2o and R, are arylalkyloxy; and R, and R, are methyl; R, is 
acyloxy; and R, is arylselenylalkyl. 
23. The compound of claim 18, wherein R, is chloro; R, 
and R, are arylalkyloxy; R, and R, are methyl; R, is 
acyloxy; and R, is methyl. 
15 and R, is methyl. 
25 24. A compound of Formula V 
(VI 
wherein R, is independently hydrido, halo, alkyl, alkenyl, 
40 alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
45 carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl,  alkoxycarbonylalkyl,  amido, 
N-alkylamido, N-N-dialkylamido, N-monoarylamido, 
N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, 
N-alkyl-N-hydroxyamidoalkyl, amidoalkyl ,  
SO aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, 
heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, 
alkylthio,  alkylsulfinyl,  N-alkylamino, N,N- 
dialkylamino, acyl, acyloxy, aryloxy, acylamino, 
amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, 
alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or 
alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, 
60 heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 
65 N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
55 
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amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 5 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
phenylselenyl, or alkylsilyloxy; 
R, is independently hydrido, halo, alkyl, alkenyl, 
alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, 
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, IO 
N - a l k y l s u l f a m y l ,  N , N - d i a l k y l s u l f a m y l ,  
N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, 
carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, 
alkoxycarbonyl, alkoxycarbonylalkyl, amido, 15 
N - a l k y l a m i d o ,  N - N - d i a l k y l a m i d o ,  
N-monoarylamido, N-alkyl-N-arylamido, N-alkyl- 
N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, 
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, 
cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, 20 
cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, 
N,N-dialkylamino, acyl,  acyloxy, aryloxy, 
acylamino, amino, cyano, nitro, sulfonate, thiol, 
arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, 
wherein, R, is OSi-t-BuMe,, X, is chloro, X, is bromo, 
with compound (3); 
p?? . -  heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, S H  
% 
to form an intermediate compound (18): 
R3 
.,@ 
. -   
R, phenylselenyl, is h droxy; and or alkylsilyloxy; 25 8 $4 $ R5 H R, is independently hydrido, alkyl, or hydroxyalkyl; R, is independently hydrido, alkyl, or hydroxyalkyl; 
R, is independently hydroxy, or alkylsilyloxy; 
or a pharmaceutically-acceptable salt thereof. 30 
25, The compound of claim 24, wherein R, is halo; R, and wherein, R1 is chloro, R2 and R3 are 
R, are arylalkyloxy; R, and R, are alkyl; R, is hydroxy; and 
R, is selected from hydroxy and alkylsilyloxy. 
26. The compound of claim 25, wherein R, is chloro; R, 
and R, are OBn; and R, and R, are methyl; R, is hydroxy; 35 comprising: 
and R, is OSi-tBuMe,. 
b) isolating said intermediate compound (18); and 
c) deprotecting said intermediate compound. 
29. A method of synthesizing (+) chloropuupehenone 
a) hydrogenating compound (19) to form compound (25); 
(25) 
27. The compound of claim 25, wherein R, is chloro; R, 
and R, are OBn; R, and R, are methyl; R, is hydroxy; and 
R, is hydroxy. OSi-t-BuMe2 
40 
28. A method of synthesizing a compound of Formula I: c1 OSi-t-BuMe2 
&R3 (1) 45 ,;5 
. -  ,
'% H 
.\O , 
b) disilylating compound (25) to form compound (26); 
(26) 
: 1 
$4 R5 
$ H  and 
55 
wherein R, is chloro, R, and R, are hydroxy; and R, and 
R, are methyl, comprising: 
a) reacting compound (4), 
R90 90q0R9 X1 X2 c 
so 
(4) 6o 
65 
(3) 
US 6,727,277 B3 
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c) oxidizing compound (26) to form (+) chloropuupe- 35. The composition of claim 34, wherein said at least one 
pharmaceutically-acceptable carrier material is selected 
from the group consisting of lactose, sucrose, starch powder, 
cellulose esters of alkanoic acids, cellulose alkyl esters, talc, 
and calcium salts of phosphoric and sulfuric acids, gelatin, 
acacia gum, sodium alginate, microcrystalline cellulose, 
sodium starch glycolate, sodium lauryl sulfate, povidone, 
polyvinylpyrrolidone, and polyvinyl alcohol. 
36. The composition of claim 34, wherein said composi- 
tion is in the form of a capsule or a liquid emulsion. 
37. The composition of claim 34, wherein said composi- 
tion is provided in a controlled release formulation. 
38. The composition of claim 37, wherein said composi- 
tion is provided as a dispersion in hydroxypropylmethyl 
cellulose. 
39. The composition of claim 34, wherein said composi- 
tion is in a formulation suitable for parenteral administra- 
tion. 
40. The composition of claim 39, wherein said formula- 
tion is a lipid emulsion. 
41. The composition of claim 34, wherein said composi- 
tion comprises a diluent selected from the group consisting 
henone (27). 
(27) 
I s stearic acid, magnesium stearate, magnesium oxide, sodium OH 
10 
30, A method for identifying a compound that inhibits 
a) administering a known amount of cholesterol and a 20 
compound of claim 1 to a non-human mammal; and 
b) measuring lymphatic absorption of said known amount 
of cholesterol, wherein a statistically significant 
decrease in said cholesterol absorption relative to the 
lymphatic absorption of cholesterol, comprising: 
lymphatic cho~estero~ absorption of a corresponding 2s Of polyethylene glycol, propylene glycol, 
control non-human mammal indicates said compound 
Oil, 
cottonseed Oil, peanut Oil, Oil, 
inhibits lymphatic absorption of cho~estero~, and 
wherein a statistically insignificant change or a statis- 
tically significant increase in said cholesterol absorp- 
tion relative to the lymphatic cholesterol absorption of 30 
a corresponding control non-human mammal indicates 
said compound does not inhibit lymphatic absorption 
of cholesterol. gangrene, and stroke. 
31. The method of claim 30, wherein said known amount 
42. A method of treating a cholesterol-related condition, 
comprising administering an effective amount of a com- 
pound Of 
43. The method of claim 42, wherein said cholesterol- 
related condition is selected from the group consisting of 
atherosclerosis, hypercholesterolemia, heart attack, 
44. The method of claim 42, wherein said compound is 
of cholesterol and said compound are administered in a lipid 3s administered orally, intravascularly, intraperitoneally, 
emulsion. subcutaneously, intramuscularly, or topically. 
45. The method of claim 42, wherein said compound is 
mammal is a rat. administered in an amount from about 4 m a g  to about 4 
gikg of body weight per day. 
mammal is fasted prior to said administering step. 46. The method of claim 42, wherein said compound is 
administered as part of a treatment regimen comprising a 
diet low in cholesterol. 
47. The method of claim 42, wherein said compound is 
administered as part of a treatment regimen comprising 
45 administering one or more HMG-CoA reductase inhibitors. 
48. The method of claim 42, wherein said mammal is a 
49. The method of claim 48, wherein said compound is 
50. The method of claim 49, wherein said compound is 
I to a 
32. The method of claim 30, wherein said non-human 
33. The method of claim 32, wherein said non-human 
34. Acomposition comprising a compound of Formula 1: 
(1) 
40 
OH, and 
human. 
administered for 7 days or more. 
administered for one year or more. 
so 
51. The method of claim 48, wherein said compound is 
administered in an amount from about 4 mgikg body weight 
ss to about 4 gikg body weight per day. 
at least one pharmaceutically-acceptable carrier material. * * * * *  
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